Drug delivery across the skin

Bibliography

• HAD GRAFT J: Advances in transdermal drug delivery. Practitioner (1996) 240:656–658.
   PubMedGoogle Scholar
• HADGRAFT J: Recent developments in topical and trans-dermal delivery. Eur. J. Drug. Metab. Pharmacokinet. (1996) 21:165–173.
   PubMed Web of Science ®Google Scholar
• •A scholarly review article by an expert in the field.
   Google Scholar
• MOORE L, CHIEN YW: Transdermal drug delivery: a re- view of pharmaceutics, pharmacokinetics and phar-macodynamics. Grit. Rev, Then Drug, Carrier. Syst. (1988) 4:285–349.
   PubMed Web of Science ®Google Scholar
• RIDOUT G, SANTUS GC, GUY RH: Pharmacokinetic con-siderations in the use of newer transdermal formula-tions. Din. Pharmacokinet (1988) 15:114–131.
   PubMedGoogle Scholar
• ROBBINS AS: Pharmacological approaches to smoking cessation. Am. J. Prey. Med. (1993) 9:31–33.
   PubMed Web of Science ®Google Scholar
• GUY RH: Percutaneous absorption: physical chemistry meets the skin. Cum Pro& Dermatol. (1995) 22:132–138.
   PubMedGoogle Scholar
• GUY RH: Current status and future prospects of trans-dermal drug delivery. Pharm. Res. (1996) 13:1765–1769.
   PubMed Web of Science ®Google Scholar
• CEVC G: Transfersomes, liposomes and other lipid sus-pensions on the skin: permeation enhancement, vesi-cle penetration and transdermal drug delivery. Grit, Rev, Then Drug Carrier, Syst. (1996) 13:257–388.
   PubMed Web of Science ®Google Scholar
• ••An extensive review outlining the basic theoretical back-ground to skin penetration.
   Google Scholar
• Transdermal Controlled Systemic Medications. Chien YW (Eds.), Marcel Dekker, New York (1987).
   Google Scholar
• Transdermal Drug Delivery. Developmental Issues and Re-search Initatives. Hadgraft J, Guy RH (Eds.), Marcel Dekker, New York (1989).
   Google Scholar
• Pharmaceutical Skin Penetration Enhancement. Walters KA, Hadgraft J (Eds.), Marcel Dekker, New York (1993) 383–408.
   Google Scholar
• Percutaneous Absorption, Bronough RL, Maibach HI (Eds.), Marcel Dekker, New York (1993).
   Google Scholar
• PATEL HM, MOGHIMI SM: Liposomes and the skin per-meability barrier. Drug Targ. Deily, (1993) 2:137–148.
   Google Scholar
• MEZEI M: Liposomes and the skin. In: Liposomes in Drug Delivery. Gregoridadis G, Florence AT, Patel H (Eds.), Har-wood Academic Publishers, Switzerland (1993):124–135.
   Google Scholar
• SCHREIER H, BOUWSTRA J: Liposomes and niosomes as topical drug carriers: dermal and transdermal drug de-livery. J. Contr. Rel. (1994) 30:1–15.
   Web of Science ®Google Scholar
• Liposome Dermatics. Braun-Falco 0, Korting HC, Maibach HI (Eds.), Springer, Berlin (1992).
   Google Scholar
• Phospholipid Handbook. Cevc G (Ed.), Marcel Dekker, New York (1993).
   Google Scholar
• Liposome Technology (Second Edition). Gregoriadis G (Ed.), CRC-Press, Boca Raton, Florida (1992).
   Google Scholar
• The Physiology and Pathophysiology of the Skin (Volume 5). Jarrett A (Ed.), Academic Press, London (1978).
   Google Scholar
• Biochemistry and Physiology of the Skin. Goldsmith LA (Ed.), Oxford University Press, New York (1983).
   Google Scholar
• BERNER B, JOHN VA: Pharmacokinetic characterisation of transdermal delivery systems. Din. Pharmacokinet. (1994) 26:121–134.
   PubMed Web of Science ®Google Scholar
• GUY RH, HADGRAFT J: Selection of drug candidates for transdermal drug delivery. Pharm. Skin Penetr. Enhanc. Walters K, Hadgraft J (Eds.), Marcel Dekker, New York (1993) :59–81.
   Google Scholar
• SINGH P, ROBERTS MS: Local deep tissue penetration of compounds after dermal application: structure-tissue penetration relationships. J. Pharmacol. Exp. Then (1996) 279:908–917.
   PubMed Web of Science ®Google Scholar
• HOGAN DJ, MAIBACH HI: Adverse dermatologic reac-tions to transdermal drug delivery systems. J. Am. Acad. Dermatol. (1990) 22:811–814.
   PubMed Web of Science ®Google Scholar
• HOLDINESS MR: A review of contact dermatitis associ-ated with transdermal therapeutic systems. Cont. Der-mal-, (1989) 20:3–9.
   Google Scholar
• •Useful account of adverse effects associated with TTS sys-tems.
   Google Scholar
• CHRISTOPHERS E, SCHUBERT C, GOOS M: The epidermis. In: Pharmacology of the skin (Volume 1). Greaves MW, Shus-ter S (Eds.), Springer-Verlag, Berlin (1989):3–30.
   Google Scholar
• Elementa Dermatologica. Christophers E, Sterry W, Schubert C, Brauer H (Eds.), Cassella-Riedel, Pharma, Frankfurt (1987).
   Google Scholar
• KRSTIC RV: Die Gewebe des Menschen und der Saugetiere. Springer, Berlin (1988).
   Google Scholar
• SCHEUPLEIN RJ: Skin permeation. In: The Physiology and Pathophysiology of the Skin (Volume 5), Jarrett A (Ed.), Aca-demic Press, London (1978):1693.
   Google Scholar
• SCHEUPLEIN RJ, BRONAUGH RL: Percutaneous absorp-tion. Biochemistry and Physiology of the Skin. Goldsmith LA (Ed.), Oxford University Press, New York (1983) :1255–1295.
   Google Scholar
• Haar und Haarkrankeiten. Ofranos CE (Ed.), Fischer Verlag, Stuttgart (1979).
   Google Scholar
• WALTERS KA, ROBERTS MS: Veterinary applications of skin penetraion enhancers. Pharmaceutical skin pene-traion enhancement, Walters K, Hadgraft J (Eds.), Marcel Dekker, New York (1993):339–358.
   Google Scholar
• KAO J, HALL J, HELMAN G: In vitro percutaneous absorp-tion in mouse skin: influence of skin appendages. Tox, App/. Pharmacol. (1988) 94:93–103.
   PubMed Web of Science ®Google Scholar
• ILLEL B, SCHAEFER H: Transfollicular percutaneous ab-sorption and skin model for quantitative studies. Acta Derm. Venerol. (1988) 68:427–430.
   PubMed Web of Science ®Google Scholar
• WARNER RR, MYERS MC, TAYLOR DT: Electron probe analysis of human skin: determination of the water concentration profile. J. Invest, Dermatol. (1988) 90:218–224.
   PubMed Web of Science ®Google Scholar
• SCHATZLEIN A, CEVC G: Permeability barrier of the in-tact skin is affected by the non-uniform cellular pack-ing in the stratum corneum. A high-resolution confocal laser scanning microscopy study with the ultradeform-able vesicles, Transfersomes. Br. J. Dermatol. (1997). (In Press.)
   Google Scholar
• SCHATZLEIN A, CEVC G: Clsm study of the skin perme-ability barrier and penetration pathways by means of ultradeformable lipid vesicles, Transfersomes. (1995). (Submitted).
   Google Scholar
• CHAPMAN SJ, WALSH A: Desmosomes, corneosomes and desquamation. An ultrastrucutral study of adult pig epidermis. Arch. Dermatol. Res. (1990) 282:304–310.
   PubMed Web of Science ®Google Scholar
• SWARTZENDRUBER DC, MANGANARO A, MADISON KC etal.: Organization of the intercellular spaces of porcine epidermal and palatal stratum corneum: a quantitative study employing ruthenium tetroxide. Cell. Tissue Res. (1995) 279(2):271–276.
   Google Scholar
• CHANG F, SWARTZENDRUBER DC, WERTZ PW, SQUIERCA: Covalently bound lipids in keratinizing epithelia. Biochim. Biophys. Acta (1993) 1150:98–102.
   PubMed Web of Science ®Google Scholar
• PLEWIG G, SCHEUBER E, REUTER B, WAIDELICH W: Thickness of corneocytes. In: Stratum Comeum, Marks R and Plewig G (Eds.), Springer-Verlag, Berlin-Heidelberg (1983) :171–174.
   Google Scholar
• CHRISTOPHERS E, WOLFF HH, LAURENCE EB: The forma-tion of epidermal cell columns. J. Invest. Dermatol. (1974) 62:555–559.
   PubMed Web of Science ®Google Scholar
• FARTASCH M: Human barrier formation and reaction to irritation. Cum Pro& Dermatol. (1995) 23:95–103.
   PubMedGoogle Scholar
• ODLAND GF: A submicroscopic granular component in human epidermis. J. Invest. Dermatol. (1962) 34:11–15.
   Web of Science ®Google Scholar
• LANDMANN L: Epidermal permeability barrier: trans-formation of lamellar granule-disks into intercellular sheets by a membran-fusion process, a freeze-fracture study. J. Invest. Dermatol. (1986) 87:202–209.
   PubMed Web of Science ®Google Scholar
• Liposome Dermatics: Chemical Aspects of the Skin Lipid Ap-proach. Braun-falco 0, Korting HC, Meibach H (Eds.), Berlin, Springer (1992).
   Google Scholar
• TSAI JC, GUY RH, THORNFELDT CR et al.: Metabolic ap-proaches to enhance transdermal drug delivery. 1. Ef-fect of lipid synthesis inhibitors. J. Pharm. Sci. (1996) 85 (6):643–648.
   Google Scholar
• WHITE R, WALKER M: Thermotropic and lyotropic be-haviour of epidermal lipid fractions. Biochem. Soc. Trans. (1990) 18:881–882.
   PubMed Web of Science ®Google Scholar
• FARTASCH M, BASSUKAS ID, DIEPGEN TL: Disturbed ex-truding mechanism of lamellar bodies in dry non-eczematous skin of atopics. British J. Dermatol. (1992) 127:221–227.
   PubMed Web of Science ®Google Scholar
• BOUVVSTRA JA, GORIS GS, VAN DER SPEK JA: Structuralinvestigations of human stratum corneum by small an-gle X-ray scattering. J. Invest. Dermatol. (1991) 97:1005–1012.
   PubMed Web of Science ®Google Scholar
• LAMPE MA, BURLINGAME AL, WHITNEY JA et al.: Humanstratum corneum lipids: characterization and regional variations. J. Lipid Res. (1983) 24:120–130.
   PubMed Web of Science ®Google Scholar
• TUR E, MAIBACH HI, GUY RH: Percutaneous penetrationof methyl nicotinate at three anatomic sites: evidence for an appendageal contribution to transport? Skin Pharmacol. (1991) 4 (4) :230–234.
   Google Scholar
• LAVRIJSEN AP, BOUWSTRA JA, GOORIS GS et al Reduced skin barrier function parallels abnormal stratum cor-neum lipid organization in patients with lamellar ich-thyosis. J. Invest. Dermatol. (1995) 105(4)619–24.
   Google Scholar
• WALTERS K A, WALKER M, OLEJNIK 0: Non-ionic surfac-tant effects on hairless mouse skin permeability char-acteristics. J. Pharm. Pharmacol. (1988) 40:525–529.
   PubMedGoogle Scholar
• WALTERS KA: Penetration enhancers and their use intransdermal therapeutic systems. In: Transdermal Drug Delivery: Developmental Issues and Research Initiatives. Hadgraft J, Guy RH (Eds.), Marcel Dekker, New York (1989):197–246.
   Google Scholar
• BOUVVSTRA JA, GOORIS GS, VAN DER SPEK JA, LAVRIJSEN S, BRAS W: The lipid and protein structure of mouse stratum corneum: a wide and small angle diffraction study. Biochim. Biophys. Acta (1994) 1212 (2): 183–192.
   PubMed Web of Science ®Google Scholar
• SCOTT RC, WALKER M, DUGARD PH: A comparison of the in vitro permeability properties of human and some laboratory animal skins. Int. J. Cosmet. Sci. (1986) 8:189–194.
   PubMed Web of Science ®Google Scholar
• SCHEUPLEIN R J: Site variations in diffusion and perme-ability. In: The Physiology and Pathophysiology of the Skin (Volume 5). Jarrett A (Ed.), Academic Press, London (1978) :1731.
   Google Scholar
• RIETSCHEL RL: Physiologic response of chronically in-flamed and accommodated human skin. Cum Pro& Dermatol. (1995) 23:104–107.
   PubMedGoogle Scholar
• POTTS RO, GUY RH. Prediciting skin permeabilitiy. Pharm. Res. (1992) 9:663–669.
   PubMed Web of Science ®Google Scholar
• BOMMANNAN D, POTTS RO, GUY RH: Examination of stratum corneum barrier function in vivo by infrared spectroscopy. J. Invest. Dermatol. (1990) 95:403–408.
   PubMed Web of Science ®Google Scholar
• ABRAM K, HARVELL JD, SHRINER D, et al.: Effect of or- ganic solvents on in vitro human skin water barrier function. J. Invest. Dermatol. (1993) 101:609–613.
   Google Scholar
• SVEDMAN P, LUNDIN S, SVEDMAN C: Administration of antidiuretic peptide (ddavp) by way of suction de-epithelialised skin. Lancet (1991) 337(8756):1506–1509.
   PubMed Web of Science ®Google Scholar
• SVEDMAN P, LUNDIN S, HOGLUND P et al.: Passive drug diffusion via standardized skin mini-erosion: meth-odological aspects and clinical findings with new de-vice. Pharm. Res. (1996) 13(9):1354–1359.
   PubMed Web of Science ®Google Scholar
• AF DAVIS, HADGRAFT J: Effect of supersaturation onmembrane transport: 1. Hydrocortisone acetate. Int. J. Pharmaceut. (1991) 76:1–8.
   Web of Science ®Google Scholar
• SURBER C, WILHELM KP, HORI M, MAIBACH HI, GUY RH:Optimization of topical therapy: partitioning of drugs into stratum corneum. Pharm. Res. (1990) 7 (12):1320–1324.
   PubMed Web of Science ®Google Scholar
• FLYNN GL: Physicochemical determinants of skin ab-sorption. In: Principles of Route-to-Route Extrapolation for Risk Assessment. Gerrity TR, Henry CJ (Eds.), Elsevier, New York (1990):93–127.
   Google Scholar
• •The most complete survey of skin permeability data pub-lished to date.
   Google Scholar
• ONGPIPATTANAKUL B, BURNETTE RR, POTTS RO, FRAN-COEUR ML: Evidence that oleic acid exists in a separate phase within stratum corneum lipids. Pharmaceut. Res. (1991) 8:350–354.
   PubMed Web of Science ®Google Scholar
• CORNWELL PA, BARRY BW, STODDART CP, BOUWSTRAJA: Wide-angle X-ray diffraction of human stratum cor-neum: effects of hydration and terpene enhancer treat-ment. J. Pharm. Pharmacol. (1994) 46(12):938–950.
   PubMed Web of Science ®Google Scholar
• POTTS RO, MAK VHW, GUY RH, FRANCOEUR ML: Strate-gies to enhance permeabilitiy via stratum corneum lipid pathways. Adv. Lipid Res. (1991) 24:173–210.
   PubMedGoogle Scholar
• ELYAN BM, SIDHOM MB, PLAKOGIANNIS FM: Evaluationof the effect of different fatty acids on the percutaneous absorption of metaproterenol sulfate. J. Pharm. Sr,. (1996) 85(1):101–105.
   PubMed Web of Science ®Google Scholar
• LAMBERT WJ, HIGUCHI WI, KNUTSON K, KRILL SL: Dose-dependent enhancement effects of azone on skin per-meability. Pharmaceut Res. (1989) 6:798.
   PubMed Web of Science ®Google Scholar
• BODDE HE, PONEC M, IJZERMAN AP: In vitro analysis ofqsar in wanted and unwanted effects of azacyclohep-tones as transdermal penetration enhancers. In: Phar-maceutical Skin Penetration Enhancement. Walters K, Hadgraft J (Eds.), Marcel Dekker, New York (1993).
   Google Scholar
• OGISO T, PAKU T, IWAKI M, TANINO T, NISHIOKA S: Per-cutaneous absorption of physiologically active pep-tides, ebiratide and elcatonin, in rats. Biol. Pharm. Bull. (1994) 17(8):1094–1100.
   PubMed Web of Science ®Google Scholar
• HOFLAND HEJ, BOUWSTRA JA, SPIES F, TALSMA H, JUNG-INGER HE: Non-ionic surfactant vesicles: a study of vesi-cle formation, characterization and stability. J. Colloid Interf Sci, (1992) 161:366.
   Web of Science ®Google Scholar
• VERMEIRE A, DE C, MUYNCK G, VANDENBOSSCHE, W: Su-crose laurate gels as a percutaneous delivery system for oestradiol in rabbits. J. Pharm. Pharmacol. (1996) 48(5)463–467.
   Google Scholar
• AKITOSHI Y, TAKAYAMA K, MACHIDA Y, NAGAI T: Effectof cyclohexanone derivatives on percutaneous absorp-tion of ketoprofen and indomethacin. Drug. Des. Deily. (1988) 2(3):239–245.
   PubMedGoogle Scholar
• DIANI AR, SHULL KL, ZAYA MJ, BRUNDEN MN: The pene-tration enhancer sepa augments stimulation of scalp hair growth by topical minoxidil in the balding stump-tail macaque. Skin Pharmacol. (1995) 8(5):221–228.
   PubMedGoogle Scholar
• JOHNSON ME, MITRAGOTRI S, PATEL A, BLANKSCHTEIN D, LANGER R: Synergistic effects of chemical enhancers and therapeutic ultrasound on transdermal drug deliv-ery. J. Pharm. Sci. (1996) 85(7):670–679.
   PubMed Web of Science ®Google Scholar
• KRILL SL, KNUTSON K, HIGUCHI WI: The influence ofiso-propanol, n-propanol and n-butanol on stratum corneum lipid phase behavior. J. Control. Rel. (1993) 25:31–42.
   Web of Science ®Google Scholar
• FRANCOEUR ML, GOLDEN GM, POTTS RO: Oleic acid: itseffects on stratum corneum in relation to (trans)der-mal drug delivery. Pharm. Res. (1990) 7:621–627.
   PubMed Web of Science ®Google Scholar
• TURUNEN TM, URTTI A, PARONEN P, AUDUS KL, RYTTINGJH: Effect of some penetration enhancers on epithelial membrane lipid domains: evidence from fluorescence spectroscopy studies. Pharm. Res, (1994) 11(2):288–294.
   PubMed Web of Science ®Google Scholar
• GOATES CY, KNUTSON K: Enhanced permeation of po-lar compounds through human epidermis. I. Perme-ability and membrane structural changes in the presence of short chain alcohols. Biochim. Biophys, Acta (1995) 1195:169–179.
   Google Scholar
• YONETO K, GHANEM AH, HIGUCHI WI, PECK KD, LI SK: Mechanistic studies of the 1-alkyl-2-pyrrolidones as skin permeation enhancers. J. Pharm, Sci. (1995) 84 (3):312–317.
   PubMed Web of Science ®Google Scholar
• •Description of a new type of skin permeation enhancer.
   Google Scholar
• AUNGST BJ: Structure/effect studies of fatty acid iso-mers as skin penetration enhancers and skin irritants. Pharmaceut. Res. (1989) 6:244.
   PubMed Web of Science ®Google Scholar
• AUNGST BJ, BLAKE JA, HUSSAIN MA: Contributions of drug solubilization, partitioning, barrier distruption and solvent permeation to the enhancement of skin permeation of various compounds with fatty acids and ammines. Pharmaceut, Res, (1990) 7:712–718.
   PubMed Web of Science ®Google Scholar
• CATZ P, FRIEND DR: Alkyl esters as skin permeation en-hancers for indomethacin. tnt. I Pharm. (1989) 55:17.
   Google Scholar
• TAKEUCHI Y, YASUKAWA H, YAMAOKA Y et al.: Destabili-zation of whole skin lipid bio, liposomes induced by skin penetration enhancers and ft, ir/atr (fourier trans-form infrared/attenuated total reflection) analysis of stratum corneum lipids. Chem, Pharm, Bull, (1992) 40:484–487.
   PubMed Web of Science ®Google Scholar
• OKUMURA M, NAKAMORI Y, SUGIBAYASHI K, MORI-MOTO Y: Enhanced skin permeation of papaverine by a medium chain glyceride. Drug Des. Deliv. (1991) 7:147–157.
   PubMedGoogle Scholar
• TAKAHASHI K, MATSUMOTO T, KIMURA T et al.: Effect of polyol fatty acid esters on diclofenac permeation through rat skin. Biol. Pharm. Bull. (1996) 19(6)893–896.
   Google Scholar
• KADIR R, TIEMESSEN HLGM, PONEC M, JUNGINGER HE, BODDE HE: Oleyl surfactants as skin penetration en-hancers: effects on human stratum corneum perme-ability and in vitro toxicity to cultured human skin cells. In: Pharmaceutical skin penetration enhancment. Walters K, Hadgraft J (Eds.), Marcel Dekker, New York (1993):215–227.
   Google Scholar
• BARRY BW, SOUTH WELL E, WOODFORD R: Optimization of bioavailability of topical steroids: penetration en-hancers under occlusion. J. Invest, Dermatol. (1984) 82:49–52.
   PubMed Web of Science ®Google Scholar
• COOPER ER: Alterations in skin permeability. In: Trans-dermal Controlled Systemic Medications, Chien YW (Ed.), Marcel Dekker, New York (1987):83–91.
   Google Scholar
• GOODMAN M, BARRY BW: Action of skin penetration enhancers on human stratum corneum as assessed by differential scanning calorimetry. In: Percutaneous Ab-sorption. Bronough RL, Maibach HI (Eds.), Marcel Dekker, New York (1993):567–593.
   Google Scholar
• FLEEKER C, WONG 0, RYTTING JH: Facilitated transport of basic and acidic drugs in solutions through snake-skin by a new enhancer-dodecyl n,n-dimethylamino acetate. Pharm. Res. (1989) 6(6):443–448.
   PubMed Web of Science ®Google Scholar
• OGISO T, NIINAKA N, IWAKI M: Mechanism for enhance-ment effect of lipid disperse system on percutaneous absorption. J. Pharm. Sci. (1996) 85(1):57–64.
   PubMed Web of Science ®Google Scholar
• OGISO T, NISHIOKA S, IWAKI M: Dissociation of insulin oligomers and enhancement of percutaneous absorp-tion of insulin. Biol. Pharm. Bull. (1996) 19(8) :1049–1054.
   PubMed Web of Science ®Google Scholar
• POTTS RO, GOLDEN GM, FRANCOEUR ML, MAK VHW, GUY RH: Mechanism and enhancement of solute trans-port across the stratum corneum. J. Contr. Rel. (1991) 15:249–260.
   Web of Science ®Google Scholar
• NAKASHIMA M, ZHAO MF, OHYA H et al.: Evaluation of invivo transdermal absorption of cyclosporin with ab-sorption enhancer using intradermal microdialysis in rats. J. Pharm. Pharmacol. (1996) 48:1143–1146.
   PubMed Web of Science ®Google Scholar
• MATSUYAMA K, NAKASHIMA M, NAKABOH Y etal.: Appli-cation of in vivo microdialysis to transdermal absorp-tion of methotrexate in rats. Pharm. Res. (1994) 11 (5) :684–686.
   Google Scholar
• BARRY BW: Optimizing percutaneous absorption. In: Percutaneous Absorption. Bronough RL, Maibach HI (Eds.), Dekker, New York (1993) :531–554.
   Google Scholar
• ALBERY WJ, HADGRAFT J: Percutaneous absorption: in vivo experiments. J. Pharm. Pharmacol, (1979) 31:140–147.
   PubMed Web of Science ®Google Scholar
• BRAIN KR, WALTERS KA: Molecular modeling of skin permeation enhancement by chemical agents. In: Phar-maceutical Skin Penetration Enhancement. Walters KA, Hadgraft J (Eds.), Marcel Dekker, New York (1993):383–408.
   Google Scholar
• SINGH SK, DURRANI MJ, REDDY IK, KHAN MA: Effect of permeation enhancers on the release of ketoprofen through transdermal drug delivery systems. Pharmazie (1996) 51(10):741–744.
   PubMed Web of Science ®Google Scholar
• OKAMOTO H, HASHIDA M, SEZAKI H: Structure-activity relationship of 1-alkyl- or 1-alkenylazacycloalkanone derivatives as percutaneous penetration enhancers. J. Pharm, Sci, (1988) 77(5):418–424.
   PubMed Web of Science ®Google Scholar
• •One of the first studies investigating the relationship between the chemistry of an enhancer and its effect on skin permeabil-ity.
   Google Scholar
• AUNGST BJ, ROGERS NJ, SHEFETER E: Enhancement of nolaxone penetration through human skin in vitro us-ing fatty acids, fatty alcohols, surfactants, sulfoxides and amides. Int. J. Pharm. (1986) 33:225–234.
   Web of Science ®Google Scholar
• CEVC G: How membrane chain-melting phase transi-tion temperature is affected by lipid chain asymmetry and the degree of unsaturation: analysis and predic-tions based on the effective chain-length model. Bio-chemistry (1991) 30/29:7186–7193.
   Google Scholar
• HORI M, SATOH S, MAIBACH HI, GUY RH: Enhancement of propranolol hydrochloride and diazepam skin ab-sorption in vitro: effect of enhancer lipophilicity. J. Pharm. Sci. (1991) 80(0:32–35.
   PubMedGoogle Scholar
• BROWN MB, MARRIOTT C, MARTIN GP: The effect of hya-luronan on the in vitro deposition of diclofenac within the skin. Int, J. Tissue. React. (1995) 17(4):133–40.
   PubMedGoogle Scholar
• BEHL CR, FLYNN GL, KURIHARA T et al.: Permeability of thermally damaged skin: I. Immediate influences of 60°C scalding on hairless mouse skin. J. Invest, Dermatol. (1980) 75:340–345.
   Google Scholar
• HOOGSTRAATE AJ, CULLANDER C, NAGELKERKE JF et al.: Diffusion rates and transport pathways of FITC-labeled model compounds through the buccal epithelium. Pharm. Res. (1994) 11(0:83–89.
   PubMedGoogle Scholar
• HOOGSTRAATE AJ, VERHOEF JC, TUK B: In-vivo buccal delivery of fluorescein isothiocyanate-dextran 4400 with glycodeoxycholate as an absorption enhancer in pigs. J. Pharm. Sci. (1996) 85(5):457–460.
   PubMed Web of Science ®Google Scholar
• HOOGSTRAATE AJ, COOS VERHOEF J, PIJPERS A et al.: In vivo buccal delivery of the peptide drug buserelin with glycodeoxycholate as an absorption enhancer in pigs. Pharm. Res. (1996) 13(8):1233–1237.
   PubMed Web of Science ®Google Scholar
• BOMMANNAN D, OKUYAMA H, STAUFFER P, GUY RH: Sonophoresis. I. The use of high-frequency ultrasound to enhance transdermal drug delivery. Pharm. Res. (1992) 9(0559–564.
   Google Scholar
• MENON GK, BOMMANNAN DB, ELIAS PM: High-frequency sonophoresis: permeation pathways and structural basis for enhanced permeability. Skin. Phar-macol. (1994) 7(3):130–139.
   PubMedGoogle Scholar
• MITRAGOTRI S, EDWARDS DA, BLANKSCHTEIN D, LAN-GER R: A mechanistic study of ultrasonically enhanced transdermal drug delivery. J. Pharm. Sci. (1995) 84 (6) 697–706.
   PubMed Web of Science ®Google Scholar
• •A scholarly paper which describes the effect of ultrasound on the skin.
   Google Scholar
• MENON GK, PRICE LF, BOMMANNAN B et al Selective obliteration of the epidermal calcium gradient leads to enhanced lamellar body secretion. J Invest. Dermatol. (1994) 102 (5) 789–795
   PubMed Web of Science ®Google Scholar
• BOMMANNAN D, MENON GK, OKUYAMA H, ELIAS PM, GUY RH: Sonophoresis. II. Examination of the mecha-nism(s) of ultrasound-enhanced transdermal drug de-livery. Pharm. Res. (1992) 9 (8) :1043–1047.
   Google Scholar
• MITRAGOTRI S, BLANKSCHTEIN D, LANGER R: Transder-mal drug delivery using low-frequency sonophoresis. Pharm. Res. (1996) 13(3):411–420.
   PubMed Web of Science ®Google Scholar
• BENSON HAE, MCELNAAY JC, HARLAND R, HADGRAFT J: Influence of ultrasound on the percutaneous absorp-tion of nicotinate esters. Pharm. Res. (1991) 8:204–209.
   PubMed Web of Science ®Google Scholar
• LEVY D, KOST J, MESHULAM Y, LANGER R: Effect of ultra-sound on transdermal drug delivery to rats and guinea pigs. J. Din. Invest. (1989) 83:2074.
   PubMed Web of Science ®Google Scholar
• VYAS SP, SINGH R, ASATI RK. Liposomally encapsulated diclofenac for sonophoresis induced systemic deliv-ery. J. Microencapsul. (1995) 12 (2) :149–154.
   Google Scholar
• SINGH J, ROBERTS MS: Transdermal delivery of drugs by iontophoresis: a review. Drug. Des. Deliv. (1989) 4(1)1–12.
   Google Scholar
• SRINIVASAN V, HIGUCHI WI, SIMS SM, GHANEM AH, BEHL CR: Transdermal iontophoretic drug delivery: mecha-nistic analysis and application to polypeptide delivery. J. Pharm. Sci. (1989) 78(5) :370–375.
   PubMed Web of Science ®Google Scholar
• •Good, review article written by opinion leaders.
   Google Scholar
• THEISS U, KUHN I, LUCKER PW: Iontophoresis: is there a future for clinical application? Methods Find, Exp, Clin, Pharmacol. (1991) 13(5):353–359.
   Google Scholar
• GREEN PG, FLANAGAN M, SHROOT B, GUY R: Iontopho-retie drug delivery. In: Pharmaceut. Skin Penetration En-hancement. Walters K, Hadgraft J (Eds.), Marcel Dekker, New York (1993):297–319.
   Google Scholar
• SINGH P, MAIBACH HI: Transdermal iontophoresis: pharmacokinetic considerations. Din. Pharmacokinet. (1994) 26(5) 327–334.
   PubMed Web of Science ®Google Scholar
• COSTELLO CT, JESKE AH: Iontophoresis: applications in transdermal medication delivery. Phys, Ther. (1995) 75 (6) :554–563.
   PubMed Web of Science ®Google Scholar
• PIKAL MJ, SHAH S: Transport mechanisms in ionto-phoresis. II. Electroosmotic flow and transference number measurements for hairless mouse skin. Pharm. Res, (1990) 7(3):213–221.
   Google Scholar
• BANGA AK CHIEN YW: Hydrogel-based iontotherapeu-tic delivery devices for transdermal delivery of pep-tide/protein drugs. Pharm, Res, (1993) 10(5):697–702.
   PubMed Web of Science ®Google Scholar
• •Good paper.
   Google Scholar
• GREEN PG, HINZ RS, KIM A, SZOKA FC JR, GUY RH: Ionto-phoretic delivery of a series of tripeptides across the skin in vitro. Pharm, Res, (1991) 8 (9):1121–1127.
   PubMed Web of Science ®Google Scholar
• CULLANDER C, GUY RH: Sites of iontophoretic current flow into the skin: identification and characterization with the vibrating probe electrode. J. Invest, DermatoL (1991) 97(1):55–64.
   PubMed Web of Science ®Google Scholar
• HEIT MC, MONTEIRO-RIVIERE NA, JAYES FL, RIVIERE JE: Transdermal iontophoretic delivery of luteinizing hor-mone releasing hormone (LHRH): effect of repeated ad-ministration. Pharm, Res. (1994) 11 (7) :1000–1003 .
   PubMed Web of Science ®Google Scholar
• AGUIELLA V, KONTTURI K, MURTOMAKI L, RAMIREZ P: Estimation of the pore size and charge density in hu-man cadaver skin. J. Contr. Rel. (1994) 32:249–257.
   Web of Science ®Google Scholar
• PIKAL MJ: Transport mechanisms in iontophoresis. I. A theoretical model for the effect of electroosmotic flow on flux enhancement in transdermal iontophoresis. Pharm, Res, (1990) 7(2):118–126.
   Google Scholar
• •Important paper discussing the factors that contribute to ion-tophoretic flow.
   Google Scholar
• KIM A, GREEN PG, RAO G, GUY RH: Convective solvent flow across the skin during iontophoresis. Pharm, Res, (1993) 10(9):1315–1320.
   PubMed Web of Science ®Google Scholar
• CRAANE VAN HINSBERG WH, BAX L, FLINTERMAN NH et al.: Iontophoresis of a model peptide across human skin in vitro: effects of iontophoresis protocol, pH and ionic strength on peptide flux and skin impedance. Pharm, Res, (1994) 11(9):1296–300.
   Google Scholar
• POTTS RO, GUY RH, FRANCOEUR ML: Routes of ionic per-meability through mammalian skin. Solid States Ionics (1992) 53–56:165–169.
   Google Scholar
• KALIA YN, GUY RH: The electrical characteristics of hu-man skin in vivo. Pharm, Res. (1995) 12(10:1605–1613.
   PubMedGoogle Scholar
• RAO G, GUY RH, GLIKFELD P et al.: Reverse iontophore-sis: noninvasive glucose monitoring in vivo in humans. Pharm, Res, (1995) 12(12):1869–1873.
   PubMed Web of Science ®Google Scholar
• PIKAL MJ, SHAH S: Transport mechanisms in ionto-phoresis. III. An experimental study of the contribu-tions of electroosmotic flow and permeability change in transport of low and high molecular weight solutes. Pharm, Res, (1990) 7(3):222–229.
   Google Scholar
• BRAND RM, IVERSEN PL: Iontophoretic delivery of a telo-meric oligonucleotide. Pharm, Res, (1996) 13 (6):851–854.
   PubMed Web of Science ®Google Scholar
• CHOI HK, FLYNN GL, AMIDON GL: Transdermal delivery of bioactive peptides: the effect of n-decylmethyl sul-foxide, pH and inhibitors on enkephalin metabolism and transport. Pharm, Res, (1990) 7(11):1099–106.
   PubMed Web of Science ®Google Scholar
• MORIMOTO K, IWAKURA Y, NAKATANI E, MIYAZAKI M, TOJIMA H: Effects of proteolytic enzyme inhibitors as absorption enhancers on the transdermal iontopho-retic delivery of calcitonin in rats. J. Pharm, Pharmacol. (1992) 44(3):216–218.
   PubMed Web of Science ®Google Scholar
• ZELTZER L, REGALADO M, NICHTER LS et al.: Iontophore-sis versus subcutaneous injection: a comparison of two methods of local anesthesia delivery in children. Pain. (1991) 44(0:73–78.
   PubMedGoogle Scholar
• MEYER DR, LINBERG JV, VASQUEZ RJ: Iontophoresis for eyelid anesthesia. Ophthalmic, Surg, (1990) 21(12):845–848.
   PubMedGoogle Scholar
• GANGAROSA LP, Sr., OZAWA A, OHKIDO M, SHIMOMURA Y, HILL JM: Iontophoresis for enhancing penetration of dermatologic and antiviral drugs. J. Dermatol, (1995) 22 (1 1) 865–875.
   Google Scholar
• CARRASCO VN, PRAZMA T, BIGGERS WP: A safe, effective anesthetic technique for outpatient myringotomy tube placement. Laryngoscope (1993) 103(1)92–93.
   Google Scholar
• SCHIFFMAN EL, BRAUN BL, LINDGREN BR: Temporoman-dibular joint iontophoresis: a double-blind random-ized clinical trial. I Orofac, Pain (1996) 10(2):157–165.
   PubMedGoogle Scholar
• LARK MR, GANGAROSA LP Sr: Iontophoresis: an effective modality for the treatment of inflammatory disorders of the temporomandibular joint and myofascial pain. Crania (1990) 8(2):108–119.
   PubMed Web of Science ®Google Scholar
• KENNARD CD, WHITAKER DC: Iontophoresis of lido-caine for anesthesia during pulsed dye laser treatment of port-wine stains. J, DermatoL Surg, OncoL (1992) 18(4):287–294.
   PubMedGoogle Scholar
• HOLZLE E, ALBERTI N: Long-term efficacy and side ef-fects of tap water iontophoresis of palmo-plantar hy-perhidrosis - the usefulness of home therapy. Dermatologica (1987) 175 (3):126–135.
   PubMedGoogle Scholar
• MORIMOTO M, HAKUTO T, MORIMOTO E et al.: Ionto-phoretic administration of indomethacin in the treat-ment of postherpetic neuralgia. Masui (1991) 40(8) :1256–1260.
   PubMedGoogle Scholar
• BREMERICH A, WIEGEL W: The treatment of neuralgi-form facial pains with the combined therapy of transcutaneous electric nerve stimulation (tens) and the iontophoresis of nonsteroidal antiphlogistics. Dtsch, Zahn. Mund Kieferheilkd Zentralbl, (1992) 80(2)81–84.
   Google Scholar
• COURY AJ, FOGT EJ, NORENBERG MS, UNTEREKER DF: Development of a screening system for cystic fibrosis. Din, Chem. (1983) 29(9):1593–1597.
   Google Scholar
• THORNTON SN, NICOLAIDIS S: Blood pressure effects of iontophoretically applied bioactive hormones in the anterior forebrain of the rat. Am], Physiol, (1993) 265(4): 826–833.
   Google Scholar
• RITSCHEL WA, SABOUNI A, HUSSAIN AS: Percutaneous absorption of coumarin, griseofulvin and propranolol across human scalp and abdominal skin. Methods Find, Exp. Clin. PharmacoL (1989) 11(10643–646.
   Google Scholar
• RAO VU, MISRA AN: Enhancement of iontophoretic per-meation of insulin across human cadaver skin. Phar-mazie (1994) 49(7):538–539.
   PubMed Web of Science ®Google Scholar
• MEYER BR, KREIS W, ESCHBACH J et al.: Transdermal ver-sus subcutaneous leuprolide: a comparison of acute pharmacodynamic effect. Din, PharmacoL Then (1990) 48(4)340–345.
   Google Scholar
• HEIT MC, WILLIAMS PL, JAYES FL, CHANG SK, RIVIERE JE: Transdermal iontophoretic peptide delivery: in vitro and in vivo. J, Pharm, Sci, (1993) 82(5):240–243.
   PubMedGoogle Scholar
• RODRIGUEZ BAYON AM, GUY RH: Iontophoresis of na-farelin across human skin in vitro. Pharm. Res. (1996) 13(5)798–800.
   Google Scholar
• VANBEVER R, MORRE ND, PREAT V: Transdermal deliv-ery of fentanyl by electroporation. II. Mechanisms in-volved in drug transport. Pharm, Res. (1996) 13 (9) :1360–1366.
   Google Scholar
• PRAUSNITZ MR, BOSE VG, LANGE R, WEAVER JC: Electro-poration of mammalian skin: a mechanism to enhance transdermal drug delivery. Proc. NatL Acad. Sci, (USA) (1993) 90:10504–10508.
   PubMed Web of Science ®Google Scholar
• VANBEVER R, LECOUTURIER N, PREAT V: Transdermal delivery of metoprolol by electroporation. Pharm, Res. (1994) 11 (11) :1657–1662.
   PubMed Web of Science ®Google Scholar
• PRAUSNITZ MR, GIMM JA, GUY RH et al.: Imaging regions of transport across human stratum corneum during high-voltage and low-voltage exposures. J. Pharm, Sci, (1996) 85(12):1363–1370.
   PubMed Web of Science ®Google Scholar
• MEZEI M, GULASEKHARAM V: Liposomes - a selective drug delivery system for the topical route of admini-stration, lotion dosage form. Life Sci, (1980) 26:1473–1477.
   PubMed Web of Science ®Google Scholar
• MEZEI M: Liposomes in the topical application of drugs: a review. In: Liposomes as Drug Carriers. Gregoriadis G (Ed.), John Wiley & Sons, New York (1988):663–677.
   Google Scholar
• HOFLAND HE, BOUWSTRA JA, BODDE HE, SPIES F, JUNG-INGER HE: Interactions between liposomes and human stratum corneum in vitro: freeze fracture electron mi-croscopical visualization and small angle X-ray scatter-ing studies. Br. J. DermatoL (1995) 132(6):853–866.
   PubMed Web of Science ®Google Scholar
• LI L, LISHKO VK, HOFFMAN RM: Liposomes can specifi-cally target entrapped melanin to hair follicles in histo-cultured skin. In vitro Cell Dev, Biol. (1993) 29A:192–194.
   PubMed Web of Science ®Google Scholar
• LAUER AC, LIEB LM, RAMACHANDRAN C, FLYNN G, WEI-NER ND: Transfollicular drug delivery. Pharm, Res. (1995) 12:179–186.
   PubMed Web of Science ®Google Scholar
• CEVC G, GEBAUER D, GOMPPER G, KROLL DM: Transport of highly deformable vesicles through narrow pores. Biochim, Biophys, Acta (1997) (In Press.)
   Google Scholar
• SHORT SM, RUBAS W, PAASCH BD, MRSNY RJ, Transport of biologically active interferon-y across human skin in vitro. Pharm, Res. (1995) 12:1140–1145.
   PubMed Web of Science ®Google Scholar
• CEVC G, BLUME G, SCHATZLEIN A, GEBAUER D, PAUL A: The skin: a pathway for the systemic treatment with patches and lipid-based agent carriers. Adv. Drug Del. Rev. (1996) 418:349–378.
   Google Scholar
• GOMPPER G, KROLL DM: Driven transport of fluid vesi-cles through narrow pores. Phys. Rev. (1995) 52:4198–4208.
   Web of Science ®Google Scholar
• SCHATZLEIN A, CEVC G: Skin penetration by phos-pholipid vesicles, Transfersomes, as visualized by means of the confocal laser scanning microscopy. In: Phospholipids: Characterization, Metabolism and Novel Bio-logical Applications. Cevc G, Paltauf F (Eds.), AOCS Press, Champain, Illinois (1995):191–209.
   Google Scholar
• CEVC G, SCHATZLEIN A, BLUME G: Transdermal drug carriers: basic properties, optimization and transfer-efficiency in the case of epicutaneously applied pep-tides. J. Contr. Rel. (1995). (In Press.)
   Google Scholar
• BODDE H, OESTMANN-KNEISSL E Measuring skin irrita- tion: biophysical techniques versus the naked eye. (1991) 1–31.
   Google Scholar
• KORTING HC, SCHMID MH, HARTINGER A et al.: Evidence for the phagocytosis of intact oligolamellar liposomes by human keratinocytes in vitro and consecutive intra-cellular disintegration. J. MicroencapsuL (1993) 10:223–228.
   PubMed Web of Science ®Google Scholar
• HOLMAN BP, SPIES F, BODDE HE: An optimized freeze fracture replication procedure for human skin. J. Invest. Dermatol. (1990) 94:332–335.
   PubMed Web of Science ®Google Scholar
• SCHUBERT R, JOOS M, DEICHER M, MAGERLE R, LASCH J: Destabilization of egg lecithin liposomes on the skin af-ter topical application measured by perturbed gamma gamma angular correlation spectroscopy (pac) with 111in. Biochim, Biophys, Acta (1993) 1150:162–164.
   PubMed Web of Science ®Google Scholar
• MEYBECK A: Past, present and future of liposome cos-metics. In: Liposome Dermatics, Braun-Falco 0, Korting HC, Maibach HI (Eds.), Springer, Berlin (1992):341–345.
   Google Scholar
• LASCH J, LAUB R, WOHLRAB W: How deep do intact lipo-somes penetrate into human skin? J. Contr. Rel. (1991) 18:55–58.
   Web of Science ®Google Scholar
• SCHUBERT R, JOOS M, DEICHER M, LASCH J: Mode of ac-tion of topically applied liposomes in dermatology and cosmetics. Proceedings of MOBBEL (1992).
   Google Scholar
• BOUWSTRA JA, HOFLAND HE, SPIES F, GOORIS GS, JUNG-INGER HE: Changes in the structure of the stratum cor-neum induced by liposomes. In: Liposome Dermatics, Braun-Falco 0, Korting HC, Maibach HI (Eds.), Springer, Ber-lin (1992):121–136.
   Google Scholar
• LASCH J, ZELLMER S, PFEIL W, SCHUBERT R: Interaction of liposomes with the human skin lipid barrier: HSCLLS as model system - DSC of intact stratum cor-neum and in situ CLSM of human skin. J. Lipos, Res. (1995) 5:99–109.
   Google Scholar
• ZELLMER S, PFEIL W, LASCH J: Interaction of phosphati-dylcholine liposomes with the human stratum cor-neum. Biochim, Biophys, Acta (1995) 1237:176–182.
   PubMed Web of Science ®Google Scholar
• GUZEK DB, KENNEDY AH, MCNEILL SC, WAKSHULL E, POTTS RO: Transdermal drug transport and metabo-lism. I. Comparison of in vitro and in vivo results. Pharm, Res. (1989) 6:33.
   PubMed Web of Science ®Google Scholar
• POTTS RO, MCNEILL SC, DESBONNET CR, WAKSHULL E: Transdermal drug transport and metabolism. II. The role of competing kinetic events. Pharm, Res. (1989) 6:119.
   Web of Science ®Google Scholar
• STEINSTRASSER I, MERKLE HP: Dermal metabolism of topically applied drugs: pathways and models recon-sidered. Pharm, Acta. Hely. (1995) 70(0:3–24.
   PubMedGoogle Scholar
• •A good introductory paper.
   Google Scholar
• BOS JD, KAPSENBERG ML: The skin immune system: progress in cutaneous biology. Immunol, Today (1993) 14:75–78.
   PubMedGoogle Scholar
• CROSS SE, WU Z, ROBERTS MS: The effect of protein binding on the deep tissue penetration and efflux of dermally applied salicylic acid, lidocaine and diazepam in the perfused rat hindlimb. J. PharmacoL Exp. Then (1996) 277(1):366–74.
   PubMed Web of Science ®Google Scholar
• CROSS SE, ROBERTS MS: Importance of dermal blood supply and epidermis on the transdermal iontopho-retic delivery of monovalent cations. J. Pharm, Sci. (1995) 84(5):584–592.
   PubMed Web of Science ®Google Scholar
• The Dermal Lymphatic Capillaries. Daróczy J (Ed.), Springer, Berlin (1989):2.
   Google Scholar
• TUIMALA RJ, VIHTAMAKI T: Individual hormone re-placement therapy. Maturitas (1996) 23 (Suppl.):87–90.
   Google Scholar
• REGINSTER JY, ALBERTA, DEROISY R et al.: Plasma con-centration of estradiol following transdermal admini-stration of systen 50 or menorest 50. Scand, J. Rheumatol, Suppl, (1996) 103:94–100.
   Google Scholar
• CEVC G, BLUME G: Lipid vesicles penetrate into intact skin owing to transdermal osmotic gradients and hy-dration force. Biochim, Biophys, Acta (1992) 1104:226–232.
   PubMed Web of Science ®Google Scholar
• PLANAS ME, GONZALEZ P, RODRIGUEZ L, SANCHEZ S, CEVC G: Noninvasive percutaneous induction of topical analgesia by a new type of drug carrier and prolonga-tion of local pain insensivity by anesthtic liposomes. Anesth, Analg. (1992) 75:615–621.
   PubMed Web of Science ®Google Scholar
• BALFOUR JA, HEEL RC: Transdermal estradiol. A review of its pharmacodynamic and pharmacokinetic proper-ties and therapeutic efficacy in the treatment of meno-pausal complaints. Drugs (1990) 40(4):561–582.
   Google Scholar
• •Good summary of a decade of experience with TTS oestra diol.
   Google Scholar
• BALFOUR JA, McTAVISH D: Transdermal estradiol. A re-view of its pharmacological profile and therapeutic po-tential in the prevention of postmenopausal osteoporosis. Drugs. Aging (1992) 2(6):487–507.
   Google Scholar
• CORSON SL: A decade of experience with transdermal estrogen replacement therapy: overview of key phar-macologic and clinical findings. Int. J. Fertil. (1993) 38 (2):79–91.
   PubMedGoogle Scholar
• RUNNEBAUM B, SALBACH B, VON HOLST T: Oral or transdermal estrogen substitution therapy in climac-teric? Geburtshilfe Frauenheilkd (1994) 54 (3) :119–30.
   PubMed Web of Science ®Google Scholar
• WISEMAN LR, MCTAVISH D: Transdermal estra-diol/norethisterone. A review of its pharmacological properties and clinical use in postmenopausal women. Drugs Aging (1994) 4(3):238–256. A survey of TTS hormone replacement therapy.
   Google Scholar
• LOBO RA, ETTINGER B, HUTCHINSON KA et al.: Estrogen replacement: the evolving role of transdermal delivery. J. Reprod, Med. (1996) 41 (Suppl. 10):781–796.
   Google Scholar
• JEWELEWICZ R: New developments in topical estrogen therapy. Fertil, Steril. (1997) 67 (1) :1–12.
   PubMed Web of Science ®Google Scholar
• ARAYA V, CONTRERAS P, AGUIRRE C, FORADORI A: Effect of a 17-13-estradiol gel preparation on hormone levels in menopausal women. Rev. Med. Chil, (19 9 5) 123 (9):1116–1121.
   Google Scholar
• CICINELLI E, CANTATORE FP, GALANTINO P et al.: Effects of continuous percutaneous estradiol administration on skeletal turnover in post-menopausal women: a 1-year prospective controlled study. Eur, J. Obstet, Gynecol, Reprod, Biol. (1996) 69(2):109–113.
   PubMed Web of Science ®Google Scholar
• FRIEND KE, HARTMAN ML, PEZZOLI SS, CLASEY JL, THOR-NER MO: Both oral and transdermal estrogen increase growth hormone release in postmenopausal women - A clinical research center study. J. Din. Endocrinol, Me-tab. (1996) 81(6):2250–2256.
   PubMed Web of Science ®Google Scholar
• GODSLAND IF, GANGAR K, WALTON C et al.: Insulin re-sistance, secretion and elimination in postmenopausal women receiving oral or transdermal hormone re-placement therapy. Metabolism(1993) 42 (7):846–853.
   PubMed Web of Science ®Google Scholar
• BELLANTONI MF, VITTONE J, CAMPFIELD AT et al.: Effects of oral versus transdermal estrogen on the growth hor-mone/ insulin-like growth factor I axis in younger and older postmenopausal women: a clinical research cen-ter study. J. Din. Endocrinot Metab. (1996) 81(8):2848–2853.
   PubMed Web of Science ®Google Scholar
• STEVENSON JC, CROOK D, GODSLAND IF, LEES B, WHITE-HEAD MI: Oral versus transdermal hormone replace-ment therapy. Int. J. Fertil, Menopausal. Stud. (1993) 38\(Supp1.1)30–35.
   Google Scholar
• SHARP CA, EVANS SF, RISTELI L et al.: Effects of low and conventional-dose transcutaneous HRT over 2 years on bone metabolism in younger and older postmeno-pausal women. Eur, J. Din. Invest. (1996) 26(9):763–771.
   PubMed Web of Science ®Google Scholar
• BARACAT E, HAIDAR M, CASTELO A et al.: Comparative bioavailability study of an once-a-week matrix versus a twice-a-week reservoir transdermal estradiol delivery systems in postmenopausal women. Maturitas (1996) 23 (3):285–291.
   PubMed Web of Science ®Google Scholar
• BOYD RA, ZEGARAC EA, ELDON MA, SEDMAN AJ, FORGUE ST: Characterization of a 7 day 17-13-estradiol transdermal delivery system: pharmacokinetics in healthy postmenopausal women. Biopharm, Drug. Dis-pos. (1996) 17(6):459–470.
   PubMed Web of Science ®Google Scholar
• KOH KK, MINCEMOYER R, BUI MN et al.: Effects of hormone-replacement therapy on fibrinolysis in post-menopausal women. New. Engl. J. Med. (1997) 336(10)683–690.
   Google Scholar
• VIINIKKA L, ORPANA A, PUOLAKKA J, PYORALA T, YLIK-ORKALA 0: Different effects of oral and transdermal hormonal replacement on prostacyclin and thrombox-ane A2. Obstet, Gynecol, (1997) 89(0:104–107.
   PubMedGoogle Scholar
• AKKAD AA, HALLIGAN AW, ABRAMS K, AL AZZAWI F: Dif-fering responses in blood pressure over 24 hours in normotensive women receiving oral or transdermal es-trogen replacement therapy. Obstet, Gynecol, (1997) 89(0:97–103.
   PubMedGoogle Scholar
• CROOK D, STEVENSON JC: Transdermal hormone re-placement therapy, serum lipids and lipoproteins. Br. J. Pract, Symp. (1996) 86 (Suppl.):17–21.
   Google Scholar
• TIKKANEN MJ: The menopause and hormone replace-ment therapy: lipids, lipoproteins, coagulation and fi-brinolytic factors. Maturitas (1996) 23(2)209–216.
   Google Scholar
• SCARABIN PY: Risk of venous thrombosis with hor-mone replacement therapy. Lancet (1 9 9 6) 348(9042):1668.
   Google Scholar
• CLEMENTE C, CARUSO MG, BERLOCO P et al.: B-Toc-op her o 1 and I3-carotene serum levels in post-menopausal women treated with transdermal estradiol and oral medroxyprogesterone acetate. Horm Motab. Res. (1996) 28(10558–561.
   Google Scholar
• HILDITCH JR, LEWIS J, ROSS AH et al A comparison of the effects of oral conjugated equine estrogen and transdermal oestradio1-17-13 combined with an oral progestin on quality of life in postmenopausal women. Maturitas (1996) 24(3):177–184.
   PubMed Web of Science ®Google Scholar
• EDMONDS DK: Add-back therapy in the treatment of endometriosis: the european experience. Br. J. Obstet, Gynaecol. (1996) 103 (Suppl. 14):10–13.
   Google Scholar
• PANSINI F, DE PAOLI D, ALBERTAZZI P et al.: Sequential addition of low dose of medrogestone or medroxypro-gesterone acetate to transdermal estradiol: a pilot study on their influence on the endometrium. Eur. J. Obstet, GynecoL Reprod, Biol. (1996) 68(1-2):137–41.
   PubMed Web of Science ®Google Scholar
• SITRUK WARE R: Comparative evaluation of oral versus non-oral hormonal treatments in menopause. J. Gyne-col, Obstet, Biol. Reprod, (1996) 25(7):688–93.
   PubMedGoogle Scholar
• HELLE SI, OMSJO IH, HUGHES SC et al.: Effects of oral and transdermal estrogen replacement therapy on plasma levels of insulin-like growth factors and IGf binding proteins 1 and 3: a cross-over study. Din, Endocrinol. (1996) 45(6)727–732.
   Google Scholar
• MARCHESONI D, DAL POZZO M, DAL MAGRO L et al.: Transdermal estroprogestins versus transdermal es-trogen plus oral dihydrogesterone replacement in menopause. J. EndocrinoL Invest, (1996) 19(5):268–272.
   Google Scholar
• DE LIGNIERES B: Transdermal dihydrotestosterone treatment of Andropause'. Ann, Med. (1993) 25(3):235–241.
   PubMed Web of Science ®Google Scholar
• NIESCHLAG E: Testosterone replacement therapy: something old, something new... Din, EndocrinoL (1996) 45 (3):261–262.
   Google Scholar
• PORCHE DJ: Treatment review. Testosterone (testo-derm). J. Assoc. Nurses. AIDS. Care (1995) 6(4):43–45.
   PubMedGoogle Scholar
• EVANS I: Amorous inclinations. Lancet (1996) 348(9024)352.
   Web of Science ®Google Scholar
• BROCKS DR, MEIKLE AW, BOIKE SC et at.: Pharmacoki-netics of testosterone in hypogonadal men after trans- dermal delivery: influence of dose. J.Pharmacol,(1996)36(8)732–739.
   Google Scholar
• MEIKLE AW, ARVER S, DOBS AS et al.: Pharmacokinetics and metabolism of a permeation- enhanced testoster-one transdermal system in hypogonadal men: influ-ence of application site. A clinical research center study. J.Endocrinol, Metab, (1996) 81 (5):1832–1840.
   PubMed Web of Science ®Google Scholar
• MEIKLE AW, ARVER S, DOBS AS et al.: Prostate size in hy-pogonadal men treated with a nonscrotal permeation-enhanced testosterone transdermal system. Urology (1997) 49(2):191–196.
   PubMed Web of Science ®Google Scholar
• Arver S, Dobs AS, Meikle AW et al.: Improvement of sexual function in testosterone deficient men treated for 1 year with a permeation enhanced testosterone trans-dermal system. J. UroL (1996)155 (5):1604–1608.
   PubMed Web of Science ®Google Scholar
• JOHNSON ME, MITRAGOTRI S, PATEL A, BLANKSCHTEIN D, LANGER R: Synergistic effects of chemical enhancers and therapeutic ultrasound on transdermal drug deliv-ery. J. Pharm, Sci, (1996) 85(7):670–679.
   PubMed Web of Science ®Google Scholar
• TODD PA, GOA KL, LANGTR. HD: Transdermal nitroglyc-erin (glyceryl trinitrate). A review of its pharmacology and therapeutic use. Drugs (1990) 40(6)880–902.
   Google Scholar
• PARKER JD, FARRELL B, FENTON T, COHANIM M, PARKER JO: Counter-regulatory responses to continuous and in-termittent therapy with nitroglycerin. Circulation (1991) 84(6):2336–2345.
   PubMed Web of Science ®Google Scholar
• BAUER JA, FUNG HL, ZHENG W et al.: Continuous versus intermittent nitroglycerin administration in experi-mental heart failure: Vascular relaxation and radio-ligand binding to adrenoceptors and ion channels. J. Cardiovasc. Pharmacol. (1993) 22(0600–608.
   PubMed Web of Science ®Google Scholar
• ZOLI M, MAGALOTTI D, GHIGI G, MARCHESINI G, PISI E: Transdermal nitroglycerin in cirrhosis. A 24-hour echo-doppler study of splanchnic hemodynamics. J. Hepatol. (1996) 25(4):498–503.
   Google Scholar
• BERRAZUETA JR, LOSADA A, POVEDA J et al: Successful treatment of shoulder pain syndrome due to supraspi-natus tendinitis with transdermal nitroglycerin. A dou-ble blind study. Pain (1996) 66(1):63–67.
   PubMed Web of Science ®Google Scholar
• HARA M, SAIKAWA T, TSUNEMATSU Y et al.: Rapid coro-nary vasodilation by nitroglycerin tapes. Jpn, Heart J. (1996) 37(5):603–610.
   PubMedGoogle Scholar
• KANDAA, YOSHIDAM, KANOU M, YAMAGUCHI K, KYUKI K: Cardiovascular effects of nt-1, a new patch form of nitroglycerin, alone and in combination with nifedip-ine in conscious dogs. J. Pharm. Pharmacol. (1995) 47(1241021–1024.
   Google Scholar
• RAMAMURTHY S, MEHAN V, KAUFMANN U et al Effect of pre-treatment with transdermal glyceryl trinitrate on myocardial ischaemia during coronary angioplasty. Heart (1996) 76(6):471–476.
   PubMed Web of Science ®Google Scholar
• SAITO T, TAKEICHI S, NAKAJIMA Y, YUKAWA N, OSAWA M: Experimental studies of methemoglobinemia due to percutaneous absorption of sodium nitrite. J. ToxicoL ToxicoL (1997) 35(0:41–48.
   PubMedGoogle Scholar
• PARKER JD, PARKER AB, FARRELL B, PARKER JO: The ef-fect of hydralazine on the development of tolerance to continuous nitroglycerin. J. Pharmacol. Exp. Then (1997) 280(2) 866–875.
   PubMed Web of Science ®Google Scholar
• KOUNIS NG, ZAVRAS GM, PAPADAKI PJ, et al.: Allergic re-actions to local glyceryl trinitrate administration. Br. J. Pract, (1996) 50(8):437–439.
   Google Scholar
• LANGLEY MS, HEEL RC: Transdermal clonidine. A pre-liminary review of its pharmacodynamic properties and therapeutic efficacy. Drugs (1988) 35 (2):123–142.
   Google Scholar
• •An early review of the performance of TTS clonidine in the praxis.
   Google Scholar
• CHEN SW, VIDT DG: Patient acceptance of transdermal clonidine. A retrospective review of 25 patients. Cleve. Cl/n. J. Med. (1989) 56(1):21–26.
   Google Scholar
• ISHII R, TAGAWA T, ISHIDA T, NARUSE T: Antihyperten-sive effects of a new transdermal delivery system for clonidine in genetic and experimental hypertensive rats. Arzneimittelforschung (1996) 46(3):261–268.
   PubMed Web of Science ®Google Scholar
• FUJIMURA A, SASAKI, M HARADA K et al.: Influences of bathing and hot weather on the pharmacokinetics of a new transdermal clonidine, m-5041t.Pharmacol.(1996) 36(10):892–896.
   Google Scholar
• NARUSE T, ISHIDA T, ISHII R, TAGAWA T: Preclinical as-sessment of a new transdermal delivery system for do- nidine (m-5041t). Fundam.Pharmacol. (1996)10(1)47–55.
   Google Scholar
• HOUSTON MC HAYS L: Transdermal clonidine as an ad-junct to nifedipine-gits therapy in patients with mild-to-moderate hypertension. Am. Heart. J, (1993) 126(4)918–923.
   Google Scholar
• BOLTRI L, MOREL S, TROTTA M, GASCO MR: In vitro transdermal permeation of nifedipine from thickened microemulsions. J. Pharm, Belg. (1994) 49(4):315–320.
   PubMedGoogle Scholar
• MCDAID DM, DEASY PB: An investigation into the trans-dermal delivery of nifedipine. Pharm, Acta. He/v. (1996) 71(4)253–258.
   Google Scholar
• RUAN LP, ZHENG JM: Research on nifedipine patch. Yao, Hsueh, Hsueh, Pao (1991) 26(0286–292.
   Google Scholar
• OGISO T, ITO Y, IWAKI M, SHINTANI A: The percutane-ous absorption of propranolol and prediction of the plasma concentration. J. Pharmacobiodyn. (1988) 11(5)349–355.
   Google Scholar
• OGISO T, SHINTANI M: Mechanism for the enhance-ment effect of fatty acids on the percutaneous absorp-tion of propranolol. J. Pharm, Sci, (1990) 79(12):1065–1071.
   PubMed Web of Science ®Google Scholar
• AHMED S, IMAI T, OTAGIRI M: Evaluation of stereoselec-tive transdermal transport and concurrent cutaneous hydrolysis of several ester prodrugs of propranolol: mechanism of stereoselective permeation. Pharm, Res. (1996) 13(10):1524–1529.
   PubMed Web of Science ®Google Scholar
• KRISHNA R, PANDIT JK: Carboxymethylcellulose-sodium based transdermal drug delivery system for propranolol. J. Pharm, Pharmacol. (1996) 48(4):367–370.
   PubMed Web of Science ®Google Scholar
• KOBAYASHI I, HOSAKA K, UENO T, Relationship be-tween the amount of propranolol permeating through the stratum corneum of guinea pig skin after applica-tion of propranolol adhesive patches and skin irrita-tion. BioL Pharm, Bull. (1996) 19(6):839–844.
   PubMed Web of Science ®Google Scholar
• TUZUN B, TUZUN Y, GUREL N et al.: Psoriasis-like lesions in guinea pigs receiving propranolol. Int. J. Dermatol. (1993) 32(2):133–144.
   PubMed Web of Science ®Google Scholar
• PARROTT AC: Transdermal scopolamine: a review of its effects upon motion sickness, psychological perform-ance and physiological functioning. Aviat, Space. Envi-ron, Med. (1989) 60(0:1–9.
   PubMedGoogle Scholar
• •A useful review of the, somewhat disputed, anti-emetic treat-ment TTS.
   Google Scholar
• EBERHART LHJ, HOLZRICHTER P, ROSCHER R: Transder-mal scopolamine for prevention of post-operative nau-sea and vomiting: no clinically relevant result in spite of reduced postoperative vomiting in general surgical and gynecologic patients. Anaesthetist (1996) 45(3):259–267.
   PubMedGoogle Scholar
• HORIMOTO Y, NAIDE M: Transdermal scopolamine patches reduce postoperative emesis in pediatric pa-tients undergoing strabismus surgery. Can. J. Anaesth. (1990) 37(094.
   PubMedGoogle Scholar
• KOCHIADAKIS GE, ROMBOLA AT, KANOUPAKIS EM et al.: Effect of transdermal scopolamine on heart rate vari-ability in patients with severe coronary heart disease. Pacing Din. Electrophysiol. (1996) 19 (10 :1867–1871.
   PubMedGoogle Scholar
• MUSKAT Y, BUKOVSKY I, SCHNEIDER D, LANGER R: The use of scopolamine in the treatment of detrusor insta-bility. J. Urol, (1996) 156(6):1989–1990.
   PubMed Web of Science ®Google Scholar
• ILLIN JC, SUTTON L, RUIZ C et al.: The effects of scopola-mine on sleep and mood in depressed patients. BioL Psychiatry (1991) 30(2):157–169.
   PubMed Web of Science ®Google Scholar
• LUETJE CM, WOOTEN J: Clinical manifestations of trans-dermal scopolamine addiction. Ear. Nose. Throat. J. (1996) 75(4):210–214.
   PubMedGoogle Scholar
• PALMER KJ, BUCKLEY MM, FAULDS D: Transdermal mi-cotine. A review of its pharmacodynamic and pharma-cokinetic properties and therapeutic efficacy as an aid to smoking cessation. Drugs (1992) 44 (3):498–529.
   Google Scholar
• •A useful review article.
   Google Scholar
• FIORE MC, JORENBY DE, BAKER TB, KENFORD SL. To-bacco dependence and the nicotine patch: clinical guidelines for effective use. JAMA. (1992) 268(19):2687–2694.
   PubMed Web of Science ®Google Scholar
• PARADISO F, H.A.R.D.Y. :The role of transdermal nico-tine therapy in smoking cessation. Can. J. Cardiovasc, Nurs, (1993) 4(2):20–23.
   PubMedGoogle Scholar
• WESTMAN EC, LEVIN ED, ROSE JE: The nicotine patch in smoking cessation. A randomized trial with telephone counseling. Arch. Intern. Med. (1993) 153 (16) :1917–1923.
   Web of Science ®Google Scholar
• GORA ML: Nicotine transdermal systems. Ann. Pharma-cother. (1993) 27(6):742–750.
   PubMed Web of Science ®Google Scholar
• GOURLAY S: The pros and cons of transdermal nicotine therapy. Med. J. Aust. (1994) 160(3) :152–159.
   PubMed Web of Science ®Google Scholar
• MONSO E: Nicotine patches. Are they really useful? Arch. Bronconeumol. (1996) 32(9):435–436.
   PubMedGoogle Scholar
• SONDERSKOV J, OLSEN J, SABROE S, MEILLIER L, OVER-VAD K: Nicotine patches in smoking cessation: a ran-domized trial among over-the-counter customers in denmark. Am. J. EpidemioL (1997) 145(4)309–318.
   Google Scholar
• CAMPBELL IA, PRESCOTT RJ and TJEDER BURTON SM: Transdermal nicotine plus support in patients attend-ing hospital with smoking-related diseases: a placebo-controlled study. Respir, Med. (1996) 90(l):47–51.
   Google Scholar
• KUPECZ D, PROCHAZKA A: A comparison of nicotine de-livery systems in a multimodality smoking cessation program. Nurse. Pract. (1996) 21 (2):77–78.
   Google Scholar
• PICKWORTH WB, FANT RV, BUTSCHKY MF, HENNING-FIELD JE: Effects of transdermal nicotine delivery on measures of acute nicotine withdrawal. J. PharmacoL Exp. Then (1996) 279(2):450–456.
   PubMed Web of Science ®Google Scholar
• SMITH TA, HOUSE RF JR, CROGHAN IT et al.: Nicotine patch therapy in adolescent smokers. Pediatrics (1996) 98(4):659–667.
   PubMed Web of Science ®Google Scholar
• KHOURY Z, COMANS P, KEREN A: Effects of transdermal nicotine patches on ambulatory ecg monitoring find-ings: a double-blind study in healthy smokers. Cardio-vasc, Drugs. Ther. (1996) 10(2):179–184.
   PubMed Web of Science ®Google Scholar
• WOOLF A, BURKHART K, CARACCIO T, LITOVITZ T: Self-poisoning among adults using multiple transdermal nicotine patches. J. Toxicol,Toxicol. (1996)34(6):691–698.
   PubMed Web of Science ®Google Scholar
• SANDBORN WJ, TREMAINE WJ, OFFORD KP et al Trans- dermal nicotine for mildly to moderately active ulcera-tive colitis. A randomized, double-blind, placebo-controlled trial. Ann. Intern. Med. (1997) 126(5):364–371.
   PubMed Web of Science ®Google Scholar
• GUSLANDI M, TITTOBELLO A: Pilot trial of nicotine patches as an alternative to corticosteroids in ulcera-tive colitis. J. Gastroenterol. (1996) 31(4):627–629.
   PubMed Web of Science ®Google Scholar
• SILVER AA, SHYTLE RD, PHILIPP MK, SANBERG PR: Case study: long-term potentiation of neuroleptics with transdermal nicotine in tourette's syndrome. J. Am. Acad. Child. Adolesc, Psychiatr, (1996) 35(12):1631–1636. ERDMANN R, SCHNEIDER U: Nicotine and tourette's syn-drome. Psychiatr. Prax. (1996) 23 (0 :41-42. YEE LY, LOPEZ JR: Transdermal fentanyl. Ann. Pharma-cother. (1992) 26(10:1393-1399. WOODROFFE MA, HAYS H: Fentanyl transdermal sys-tem. Pain management at home. Can. Earn. Physician (1997) 43:268-272. The most recent discussion of pros and cons of TTS delivery of fentanyl.
   Google Scholar
• KORTE W, DE, STOUTZ N, MORANT R: Day-to-day titra-tion to initiate transdermal fentanyl in patients with cancer pain: short- and long-term experiences in a pro-spective study of 39 patients. J. Pain. Symptom. Manage. (1996) 11(3):139–146.
   PubMed Web of Science ®Google Scholar
• CHRISTENSEN ML, WANG WC, HARRIS S, EADES SK, WILI-MAS JA: Transdermal fentanyl administration in chil-dren and adolescents with sickle cell pain crisis. J. Pediatr. HematoL OncoL (1996) 18(4).372-376. THYSMAN S, PREAT V: In vivo iontophoresis of fentanyl and sufentanil in rats. Anesth. Analg. (1993) 77(1):61–66. DONNER B, ZENZ M, TRYBA M, STRUMPF M: Direct con-version from oral morphine to transdermal fentanyl: a multicenter study in patients with cancer pain. Pain (1996) 64(3):527–534.
   Google Scholar
• LEELANUNTAKIT S: Management of cancer-related pain with transdermal fentanyl. J. Med. Assoc. Thai. (1996) 79(6)341–346.
   Google Scholar
• BLACKWELL N: A timely change of fentanyl patch. Pal-Hat. Med. (1996) 1O(4):349.
   Google Scholar
• DAVIES AN, BOND C: Transdermal fentanyl and the opioid withdrawal syndrome. Pa/hat. Med. (1996) 10(0348.
   Google Scholar
• HUNT R: Transdermal fentanyl and the opioid with-drawal syndrome. Pa/hat. Med. (1996) 10(4):347–348.
   Google Scholar
• DEUTSCH ES, NADKARNI VM: Clonidine prophylaxis for narcotic and sedative withdrawal syndrome following laryngotracheal reconstruction. Arch. Otolaryngol. Head. Neck. Surg. (1996) 122(10:1234–1238.
   PubMedGoogle Scholar
• ROY SD, FLYNN GL: Transdermal delivery of narcotic analgesics: Comparative permeabilities of narcotic an-algesics through human cadaver skin. Pharmaceut. Res. (1989) 6:825.
   PubMed Web of Science ®Google Scholar
• DAVIS RW: Successful treatment for phantom pain. Or-thopedics (1993) 16(6):691–695.
   PubMed Web of Science ®Google Scholar
• EHRENSTROM REIZ GM, REIZ SL: EMLA-A eutectic mix-ture of local anaesthetics for topical anaesthesia. Acta. AnaesthesioL Scand. (1982) 26(6):596–598.
   PubMed Web of Science ®Google Scholar
• •The original report on a cleverly designed pharmaceutical formulation with exceptionally high drug content and good therapeutic effect.
   Google Scholar
• CALAMANDREI M, MESSERI A, BUSONI P et al Compari- son of two application techniques of EMLA and pain as-sessment in pediatric oncology patients. Reg Anesth (1996) 21(6):557–560.
   PubMedGoogle Scholar
• TISELIUS HG: Cutaneous anesthesia with lidocaine-prilocaine cream: a useful adjunct during shock wave lithotripsy with analgesic sedation. J. Urol. (1993) 149 (1):8–11.
   PubMed Web of Science ®Google Scholar
• GOURRIER E, KAROUBI P, EL HANACHE A et al.: Use of EMLA cream in premature and full-term newborn in-fants. Study of efficacy and tolerance. Arch. Pediatr. (1995) 2(10:1041–1046.
   Google Scholar
• ROWBOTHAM MC, DAVIES PS, VERKEMPINCK C, GALER BS: Lidocaine patch: double-blind controlled study of a new treatment method for post-herpetic neuralgia. Pain (1996) 65(0:39–44.
   PubMedGoogle Scholar
• ROWBOTHAM MC, DAVIES PS, FIELDS HL: Topical lido-caine gel relieves postherpetic neuralgia. Ann. Neurol. (1995) 37(2):246–253.
   PubMed Web of Science ®Google Scholar
• BARTFIELD JM, RACCIO-ROBAK N, SALLUZZO RF: Does topical lidocaine attenuate the pain of infiltration of buffered lidocaine? Acad. Emerg. Med. (1995) 2(2):104–108.
   Web of Science ®Google Scholar
• BASSETT IB, DELANEY TA, FREEMAN S: Can injected lig-nocaine cause allergic contact dermatitis? Australas. J. DermatoL (1996) 37(3):155–156.
   Google Scholar
• LAWSON RA, SMART NG, GUDGEON AC, MORTON NS: Evaluation of an amethocaine gel preparation for per-cutaneous analgesia before venous cannulation in chil-dren. Br. J. Anaesth. (1995) 75(3):282–285.
   PubMed Web of Science ®Google Scholar
• FLOUVAT B, ROUX A, DELHOTAL LANDES B: Pharma-cokinetics of ketoprofen in man after repeated percuta-neous administration. Arzneimittelforschung (1989) 39 (7) :812–815.
   PubMed Web of Science ®Google Scholar
• SHAH AK, WEI G, LANMAN RC, BHARGAVA VO, WEIR SJ: Percutaneous absorption of ketoprofen from different anatomical sites in man. Pharm. Res. (1996) 13(1):168–172.
   PubMed Web of Science ®Google Scholar
• VALENTA C, KERNER A: Effect of various vehicles on ke-toprofen permeation across artificial membranes and excised rat skin. Pharmazie. (1996) 51(8)605–606.
   Google Scholar
• BERNER G, ENGELS B, VOGTLE JUNKERT U: Percutaneous ibuprofen therapy with trauma-dolgit gel: bioequiva-lence studies. Drugs Exp. Chin. Res. (1989) 15(11-12):559–564.
   PubMedGoogle Scholar
• WAGENER HH, VOGTLE JUNKERT U: Evaluation of drug concentration in tissues after percutaneous admini-stration of non-steroidal antirheumatics. Arzneimittel-forschung (1996) 46(3):299–301.
   PubMedGoogle Scholar
• FIGUERAS A, CAPELLA D, CASTEL JM, LAORTE JR. Sponta-neous reporting of adverse drug reactions to non-steroidal anti-inflammatory drugs. A report from the spanish system of pharmaco-vigilance, including an early analysis of topical and enteric-coated formula-tions. Eur. J. Chin. Pharmacol. (1994) 47(0297–303.
   Google Scholar
• SINGH P, ROBERTS MS: Skin permeability and local tis-sue concentrations of non-steroidal. J. PharmacoL Exp. Ther. (1994) 268:144–151.
   PubMed Web of Science ®Google Scholar
• RIESS W, SCHMID K, BOTTA L etal.: Die perkutane Re-sorption von Diclofenac. Arzeim. Forsch. Drug. Res. (1986) 36:1092–1096.
   PubMed Web of Science ®Google Scholar
• RADERMACHER J, JENTSCHD, SCHOLL MA, LUSTINETZ T, FROLICH JC: Diclofenac concentration in synovial fluid and plasma after. Br. J. Clin. Pharmacol. (1991) 31:537–541.
   PubMed Web of Science ®Google Scholar
• ROSENTHAL M, BAHOUS I: A controlled clinical study on the new topical dosage form of dhep plasters in pa-tients suffering from localized inflammatory diseases. Drugs Exp. Chin. Res. (1993) 19:99–105.
   PubMedGoogle Scholar
• ASSANDRI A, CANALI S, GIACHETTI C: Local tolerability and pharmacokinetic profile of a new transdermal. Drugs. Exp. Din. Res. (1993) 19:89–95.
   PubMedGoogle Scholar
• GALLACCHI G, MARCOLONGO R: Pharmacokinetics of Drugs. Exp. Din. Res. (1993) 1:95–97.
   Google Scholar
• FRIEDMAN DI, SCHWARZ JS, WEISSPAPIR M: Submicron emulsion vehicle for enhanced trans-dermal delivery of steroidal and nonsteroidal antiinflammatory drugs. J. Pharm. Sci. (1995) 84(3):324–329.
   PubMed Web of Science ®Google Scholar
• HIRAMATSU Y, AKITA S, SALAMIN PA, MAIER R: Assess-ment of topical non-steroidal anti-inflammatory drugs. Arzneimittelforschung (1990) 40:1117–1124.
   PubMed Web of Science ®Google Scholar
• CEVC G, BLUME G: New, highly efficient formulation of diclofenac for the topical, transdermal administration in ultradeformable drug carriers, Transfersomes. (Sub-mitted).
   Google Scholar
• OKABE H, TAKAYAMA K, NAGAI T: Percutaneous ab-sorption of ketoprofen from acrylic gel patches con-taining d-limonene and ethanol as absorption enhancers. Chem. Pharm. Bull. Tokyo (1992) 40(7):1906–1910.
   PubMed Web of Science ®Google Scholar
• MASTROLONARDO M, LOCONSOLE F, RANTUCCIO F: Conjugal allergic contact dermatitis from ketoprofen. Contact Dermatitis (1994) 30(2):110.
   PubMed Web of Science ®Google Scholar
• MOZZANICA N, PIGATTO PD: Contact and photocontact allergy to ketoprofen: clinical and experimental study. Contact Dermatitis (1990) 23 (5):336–340.
   PubMed Web of Science ®Google Scholar
• TOSTI A, GADDONI G, VALERI F, BARDAZZI F: Contact al-lergy to ketoprofen: report of 7 cases. Contact. Dermati-tis (1990) 23(2):112–113.
   PubMed Web of Science ®Google Scholar
• WAIKAKUL S, DANPUTIPONG P, SOPARAT K: Topical an-algesics, indomethacin plaster and diclofenac emulgel for low back pain: a parallel study. J. Med. Assoc. Thai. (1996) 79(8):486–490.
   PubMedGoogle Scholar
• DE BENEDITTIS G, LORENZETTI A: Topical aspirin/di-ethyl ether mixture versus indomethacin and diclofe-nac/diethyl ether mixtures for acute herpetic neuralgia and postherpetic neuralgia: a double-blind crossover placebo-controlled study. Pain (1996) 65(1)45–51.
   Google Scholar
• VAN DEN OUVVELAND FA, EENHOORN PC, TAN Y, GRIB-NAU FW: Transcutaneous absorption of naproxen gel. Eur.Pharmacol. (1989) 36(2):209–211.
   Web of Science ®Google Scholar
• MORRA P, BARTLE WR, WALKER SE, LEE SN, BOWLES SK, REEVES SA: Serum concentrations of salicylic acid fol-lowing topically applied. Ann. Pharmacother. (1996) 30(9)935–940.
   Google Scholar
• SINGH P, ROBERTS MS: Iontophoretic transdermal de-livery of salicylic acid and lidocaine to. J. Pharm. (1993) 82(2):127–131.
   PubMed Web of Science ®Google Scholar
• KEIMOWITZ RM, FITZGERALD D: Transdermal aspirin and gastric ulcer healing after coronary artery stent placement. Circulation (1996) 94(11)3002.
   Web of Science ®Google Scholar
• DINSLAGE S, DIESTELHORST M, HILLE T, OTTO K: A new transdermal delivery system for pilo-carpine in glau-coma treatment. Gen J. Ophthalmol. (1996) 5(5):275–280.
   PubMedGoogle Scholar
• PELUSO AM, MISCIALI C, VINCENZI C, TOSTI A: Diffuse hypertrichosis during treatment with 5% topical mi-noxidil. Br. J. Dermatol. (1997) 136(0:118–120.
   PubMedGoogle Scholar
• TENJARLA S, PURANAJOTI P, KASINA R, MANDAL T: Terbu-taline transdermal delivery: Preformulation studies and limitations of in-vitro predictive parameters. J. Pharm. Pharmacol. (1996) 48(11) :1138–1142.
   PubMed Web of Science ®Google Scholar
• LABRIE C, FLAMAND M, BELANGER A, LABRIE F: High bioavailability of dehydroepiandrosterone adminis-tered percutaneously in the rat. J. Endocrinol. (1996) 150 (Suppl.) 107–118.
   Google Scholar
• FRIEND DR, PHILLIPS SJ, HILL JR: Cutaneous effects of transdermal levonorgestrel. Food. Chem. Toxicol. (1991) 29(9)639–646.
   Google Scholar
• WENNBERG AM, LINDHOLM LE, ALPSTEN M, LARKO 0: Treatment of superficial basal cell carcinomas using topically applied delta-aminolaevulinic acid and a fil-tered xenon lamp. Arch. Dermatol. Res. (1996) 288 (10):561–564.
   PubMed Web of Science ®Google Scholar
• OGISO T, IWAKI M, TANINO T, PAKU T: Effectiveness of the elcatonin transdermal system for the treatment of osteoporosis and the effect of the combination of elca-tonin and active vitamin d3 in rat. Biol. Pharm. Bull. (1993) 16(9):895–898.
   PubMed Web of Science ®Google Scholar
• JADOUL A, MESENS J, CAERS W et al.: Transdermal per-meation of alniditan by iontophoresis: in vitro optimi-zation and human pharmacokinetic data. Pharm. Res. (1996) 13 (9) :1348–1353.
   PubMed Web of Science ®Google Scholar
• NISHIHATA T, KOTERA K, NAKANO Y, YAMAZAKI M: Rat percutaneous transport of diclofenac and influence of hydrogenated soya phospholipid. Chem. Pharm. Bull. (1987) 35:3807–3812.
   PubMed Web of Science ®Google Scholar
• MAFFEI FACINO R, CARINI M, ALDINI G, SAIBENE L, MAC-CIOCCHI A: Antioxidant profile of nimesulide, indomethacin and diclofenac. Int. J. Tiss. React. (1993) 15:225–234.
   PubMedGoogle Scholar
• MONTI D, CHETONI P, BONALDI S, MARIOTTI BIANCHI L, SAETTONE MF: Preparation and "in vitro" and "in vivo" evaluation of a transdermal formulation containing methimazole. Boll. Ch/m. Farm. (1996) 135(2) :139–141.
   PubMedGoogle Scholar
• PARISER DM, PARISER RJ, BRENEMAN D et al Calcipotri- ene ointment applied once a day for psoriasis: A. Arch. Dermatol (1996) 132 (12) 1527
   PubMed Web of Science ®Google Scholar
• OHTA T, OKABE K, AZUMAY, KIYOKI M: In vivo microau-toradiography of 3H1,24(OH)2D3(tacalcitofi. Arch. Der-matol. Res. (1996) 288(4):188–196.
   Google Scholar
• WEINSTEIN GD: Safety, efficacy and duration of thera-peutic effect of tazarotene. Br. J. Dermatol. (1996) 135 (Suppl. 49):32–36.
   Google Scholar
• MALONEY JM, BEZZANT JL, STEPHEN RL, PETELENZ TJ: Iontophoretic administration of lidocaine anesthesia in office practice. An appraisal. J. Dermatol. Surg. Oncol. (1992) 18 (11):937–940.
   PubMed Web of Science ®Google Scholar
• JAW FS, WANG CY, HUANG YY: Portable current stimula-tor for transdermal iontophoretic drug delivery. Med. Eng. Phys. (1995) 17(5):385–386.
   PubMed Web of Science ®Google Scholar
• WILLIAMS PL, RIVIERE JE: An mechanical model describ-ing transdermal iontophoretic delivery of lidocaine. J. Pharm. Sci. (1993) 82(10:1080–1084.
   PubMedGoogle Scholar
• OSHIMA T, KASHIKI K, TOYOOKA H, MASUDA A, AMAHA K: Cutaneous iontophoretic application of condensed lidocaine. Can. J. Anaesth. (1994) 41(8):677–679.
   PubMed Web of Science ®Google Scholar
• WELKOBORSKY HJ, BUMB P: Results of tinnitus therapy using lidocaine iontophoresis. LaryngoL RhinoL OtoL Stuttg. (1988) 67(6):289–293.
   PubMedGoogle Scholar
• LAFFREE JB, VERMEIJ P, HULSHOF JH: The effect of ionto-phoresis of lignocaine in the treatment of tinnitus. Otolaryngol. (1989) 14(5):401–404.
   Google Scholar
• TANIGUCHI K, MIYAGAWA A, MIZUTANI A, HONDA N, OYAMA T: The effect of calcium channel antagonist ad-ministered by iontophoresis on the pain threshold. Acta, Anaesthesiol, Belg, (1995) 46(2):69–73.
   PubMedGoogle Scholar
• MEZEI ML: Liposomes as a skin drug delivery system. In: Topics in Pharamceutical Sciences. Breimer DD, Speiser P (Eds.), Elsevier, Amsterdam, (1985):345–358.
   Google Scholar
• SCHUBERT R, JOOS M, DEICHER M, LASCH J: Mode of ac-tion of topically applied liposomes in dermatology and cosmetics. Proc, Mobbel. (1992) 6:20–32.
   Google Scholar
• RASKOVIC D, PIAZZA P: Liposomes: a promising future for dermatocosmetology and clinical dermatology. J. Liposome Res. (1993) 3:737–751.
   Google Scholar
• HANDJANI-VILA RM, GUESNET JH: Liposomes: a promis-ing future in dermatology. Ann. Dermatol, Venerol, (1989) 116:423–438.
   PubMed Web of Science ®Google Scholar
• ASHTON P, HADGRAFT J, WALTERS KA: Effects of surfac-tants in percutaneous absorption. Pharm, Acta Hely. (1986) 61:228.
   PubMedGoogle Scholar
• OZER AY, HINCAL AA, BOUWSTRA JA: Eur, J. Pharm, Bio-pharm. (1991) 37:75.
   Google Scholar
• KROWCZYNSKI L, STOZEK T: Liposomes als wirkstoffträger in der percutanen therapie. Pharmazie (1984) 39:627–629.
   PubMed Web of Science ®Google Scholar
• EGBARIA K, RAMACHANDRAN C, WEINER N: Topical ap-plication of liposomally entrapped cyclosporin evalu-ated by in vitro diffusion studies with human skin. Skin PharmacoL (1991) 4:21–28.
   PubMedGoogle Scholar
• DOWTON SM, HU Z, RAMACHANDRAN C, WALLACH DFH, WEINER N: Influence of liposomal composition on topi-cal delivery of encapsulated cyclosporin a 1. An in vitro study using hairless mouse skin. Stp Pharma, Sci. (1993) 3:404–407.
   Google Scholar
• MASINI V, BONTE F, MEYBECK A, WEPIERRE J: Cutaneous bioavailability in hairless rats of tretinoin in liposomes or gel. Pharm, Sci, (1993) 82:17–21.
   PubMed Web of Science ®Google Scholar
• FOONG WC, HARSANYI BB, MEZEI M: Biodisposition and histological evaluation of topically applied retinoic acid in liposomal, cream and gel dosage forms. In: Phos-pholipids - Biochemical, Pharmaceutical and Analytical Considerations, Hanin I, Pepeu G (Eds.), Plenum Press, New York (1990).
   Google Scholar
• LASIC DD: Liposomes, CRC Press, Boca Raton, Florida (1993).
   Google Scholar
• BANGHAM AD, STANDISH MM, WATKINS JC: Diffusion of univalent ions across the lamellae of swollen phos-pholipids. J. Mol, Biol. (1965) 13:238–252.
   PubMed Web of Science ®Google Scholar
• HOFLAND HEJ, VANDER GEEST R, BOUWSTRA JA, BODDE HE, JUNGINGER HE: Estradiol permeation from non-ionic surfactant vesicles through human stratum cor-neum in vitro. Pharm, Res, (1994) 11:659–664.
   PubMed Web of Science ®Google Scholar
• HOFLAND HE, BOUWSTRA JA, VERHOEF JC et al Safety aspects of non-ionic surfactant vesicles: a toxicity study related to the physicochemical characteristics of non-ionic surfactants. J. Pharm, PharmacoL (1992) 44(4)287–294.
   Google Scholar
• PAUL A, CEVC G, BACHHAWAT BK: Transdermal immu-nization with large proteins by means of ultradeform-able drug carriers. Eur, J. ImmunoL (1995) (Submitted.)
   Google Scholar
• CEVC G. Dermal insulin. In: Frontiers in Insulin Pharma-cology. Berger M, Gries A (Eds.), Georg Thieme, Stuttgart (1993) :161–169.
   Google Scholar
• CEVC G, SCHATZLEIN A, GEBAUER D, BLUME G: Ultra-high efficiency of drug and peptide transfer through the intact skin by means of novel drug carriers, Trans-fersomes. In: Prediction of Percutaneous Penetration, 3rd International Conference, 14–16 April 1993 (Volume 3b), Brain KR, James VJ, Walters KA (Eds.), STS Publishing, Car-diff, UK (1993):226–236.
   Google Scholar
• CEVC G, GEBAUER D, SCHATZLEIN, A, BLUME G: Ultraf-lexible vesicles, Transfersomes, have an extremely low permeation esistance and transport therapeutic amounts of insulin across the intact mammalian skin. Biotechnology (1995) (Submitted.)
   Google Scholar
• STOZEK T, KROWCZYNSKI L: The effect of entrapment of procaine hydrochloride in liposomes on its local anes-thetic action. Pharmazie (1989) 44:466–468.
   PubMed Web of Science ®Google Scholar
• GESZTES A, MEZEI M: Topical anesthesia of the skin by liposome-encapsulated tetracaine. Anesth, Analg. (1988) 67:1079–1081.
   PubMed Web of Science ®Google Scholar
• FOLDVARI M, GESZTES A, MEZEI M: Dermal drug delivery by liposome encapsulation: clinical and electron mi-croscopic studies. J. Microencapsul. (1990) 7:479–489.
   PubMed Web of Science ®Google Scholar
• PRICE CI, HORTON JW, BAXTER CR: Topical liposomal delivery of antiibiotics in soft tissue infection. J. Surg. Res. (1990) 49:174–178.
   PubMed Web of Science ®Google Scholar
• PAUL A, CEVC G: Non-invasive administration of pro-tein antigens. Epicutaneous immunization with the bo-vine serum albumin. Vacc, Res. (1995) 4:145–164.
   Google Scholar
• KALKO N, CAJKOVAC M, JELSENJAK I: Liposomes with clindamycin hydrochloride in the therapy of acne vul-garis. Int. J. Pharmaceutics (1992) 85:97-101. HANEL H, BRAUN B, JOVIC N: DU PLESSIS J, EGBARIA K, RAMACHANDRAN C, WEINER N: Topical delivery of liposomally encapsulated gamma-interferon. Ant/v. Res. (1992) 18:259–265.
   Google Scholar
• NATSUKI T, TOMOMICHI S, MATSUO R, TAKABATAKE E, NAKANISHI M: Absorption and excretion of indometha-cin gel ointment containing egg lecithin. J. Pharmacobio-Dyn. (1986) 9:12.
   PubMedGoogle Scholar
• MICHEL C, PURMANN TH, MENTRUP E, MICHEL G, KREUTER J: Effect of liposomes on percutaneous pene-tration of lipophilic materials. Int. J. Pharmaceut. (1992) 84:93–105.
   Web of Science ®Google Scholar
• GANESAN MG, WEINER ND, FLYNN GL, HO NFH: Influ-ence of liposomal drug entrapmenton percutaneous absorption. Int. J. Pharm. (1984) 20:139–154.
   Web of Science ®Google Scholar
• LASCH J, WOHLRAB W: Liposome-bound cortisol: a new approach to cutaneous therapy. Biomed Biochim. Acta, (1986) 45: 1295–1259.
   PubMedGoogle Scholar
• WOHLRAB W, LASCH J: Penetration kinetics of liposo-mal nedrocortisone in human skin. Dermatologica (1987) 174:18–22.
   PubMedGoogle Scholar
• JACOBS M, MARTIN GP, MARIOTT C: Effect of phosphti-dyl choline on the topical bioavialability of corticoster-oids assessd by the human skin blanching assay. J. Pharm, Pharmacol, (1988) 40:829–833.
   PubMed Web of Science ®Google Scholar
• KORTING HC, ZIENICKI H, SCHAFER-KORTING M, BRAUN-FALCO 0: Liposome encapsulation improves ef-ficacy of betamethasone diproprionate in atopic ec-zema but not in psoriasis vulgaris. Eur, Pharmacol, (1990) 39:349–351.
   Google Scholar
• SCHAFER-KORTING M: Topical glucocorticoids: what has been achieved? What is still to be done? Cum Probl, Dermatol, (1993) 21:192–201.
   Google Scholar
• VERMORKEN AJ, HUKKELHOVEN MW, VERMEESCH-MARKSLAG AM et al.: The use of liposomes in the topical application of steroids. J. Pharm, Pharmacol. (1984) 36:334–336.
   PubMed Web of Science ®Google Scholar
• MORENO G: Photosensitization of mammalian cells by psoralens and porphyrins. Biochimie (1986) 68:869–873.
   PubMed Web of Science ®Google Scholar
• ARTMANN C, RODING J, GHYCZY M, PRATZEL HG: Lipo-somes from soya phospholipids as percutaneous drug carriers. 2nd Communication: quantitative in vivo in-vestigations with radioactively labelled liposomes. Arzneimittelforschung/Drug Res. (1990) 401:1365–1368.
   Google Scholar
• ARTMANN C, RODING J, GHYCZY M, PRATZEL HG: Lipo-somes from soya phospholipids as percutaneous drug carriers. 1st Communication: qualitative in vivo investi-gations with antibody-loaded liposomes. Arzneimittel-forschung/Drug Res. (1990) 40:1363–1365.
   Google Scholar
• LI L, MARGOLIS LB, LISHKO VK, HOFFMAN RM: Product, delivering liposomes specifically target hair follicles in histocultured intact skin. In Vitro Cell Dev, Biol. (1991) 28A:679–681.
   Web of Science ®Google Scholar
• ALEXANDER MY, AKHURST RJ: Liposome-medicated gene transfer and expression via the skin. Hum Mel Genet. (1995) 4(12):2279–2285.
   PubMed Web of Science ®Google Scholar
• WEINER N, WILLIAMS N, BIRCH G et al.: Topical delivery of liposomally encapsulated interferon evaluated in a cutaneous herpes guinea pig model. Antimicrob, Agents Chemother, (1989) 33:1217–1221.
   PubMed Web of Science ®Google Scholar
• EGBARIA K, RAMACHANDRAN C, WEINER N: Topical de-livery of ciclosporin: evaluation of various formula-tions using in vitro diffusion studies in hairless mouse skin. Skin Pharmacof (1990) 3:21–28.
   PubMedGoogle Scholar
• MELNIKOV VR, KOBRINSKII GD, LVOV ND, BOLOTIN I, BARINSKII IFM: Treatment of experimental genital her-pes with liposomal interferon. Vestn, Akad, Med, Nauk SSSR. (1990) 35–37.
   Google Scholar
• MIYACHI Y, IMAMURA S, NIWA Y: Decreased skin super-oxide dismutase activity by a single exoposure of ultra-violet radiation is reduced by lipsomal superoxide dismutase pretreatement. J. Invest. Dermatol, (1987) 89:111–112.
   PubMed Web of Science ®Google Scholar
• SUZUKI S, MIYACHI Y, NIWA Y, ISSHIKI N: Significance of reactive oxygen species in distal flap necrosis and its salvage with liposomal sod. Br. J. Plast. Surg. (1989) 42:559–564.
   PubMedGoogle Scholar
• LEFAIX JL, DELANIAN S, LEPLAT JJ et al.: Radiation, in-duced cutaneo, muscular fibrosis (II, major therapeutic efficacy of liposomal CU/ZN superoxide dismutase). Bull, Canc., (1993) 80:799–807.
   PubMed Web of Science ®Google Scholar
• VUTLA NB, BETAGERI GV, BANGA AK: Transdermal ion-tophoretic delivery of enkephalin formulated in lipo-somes. J. Pharm, Sci. (1996) 85 (0 :5–8.
   PubMedGoogle Scholar
• LIEB LM, RAMACHANDRAN CH, EGABRIA K, WEINER N: Topical delivery enhancment with multilamellar lipo-somes into pilosebaceous units. I. In vitro evaluation using fluorescent techniques with hamster ear model. J. Invest. Dermatol. (1992) 99:108–112.
   PubMed Web of Science ®Google Scholar
• THIBAULT B, POELMAN MC: Preparation of retinoic acid liposomes for cutaneous administration. Congr, Int, Technol, Pharm. (1989) 5:395–398.
   Google Scholar
• MEYBECK A: Past, present and future of liposome cos-metics. In: Liposome Dermatics. Braun-Falco 0, Korting HC, Maibach HI (Eds.), Springer, Berlin(1992):341–345.
   Google Scholar
• SZULC J, WOYCZIKOWSKI B, SZCZEPANSKA M et al.: Influ-ence of lecithins on the skin absorption of vitamins A and e from liposomes. Pharmazie (1994) 49:295.
   PubMed Web of Science ®Google Scholar
• YAROSH D, ALAS LG, YEE V et al.: Pyrimidine dimer re-moval enhanced by dna repair liposomes reduces the incidence of UV skin cancer in mice. Cancer Res. (1992) 52:4227–4231.
   PubMed Web of Science ®Google Scholar
• THIELE B, GHYCZY M, LUNOW C, TEICHERT HM, WOLFF HH: Influence of phospholipid liposomes (PLI) on UVB induced erythema formation. Arch, Dermatol, Res, (1993) 285:428–431.
   PubMed Web of Science ®Google Scholar
• BROWN GL, CURTSINGER LJ, WHITE M et al.: Acceleration of tensile strength of incisions treated with EgF and tgf-beta. Ann. Surg. (1988) 208:788–794.
   PubMed Web of Science ®Google Scholar
• YERUSHALMI N, ARAD A, MARGALIT R: Molecular and cellular studies of hyaluronic acid-modified liposomes as bioadhesive carriers for topical drug delivery in wound healing. Arch, Biochem, Biophys. (1994) 313:267–273.
   PubMed Web of Science ®Google Scholar
• CEVC G, BLUME G, SCHATZLEIN D: Transfersomes medi-ated transepidermal delivery improves the regio-specificity and biological activity of corticosteroids in vivo. J. Contr. Rel. (1996) 45:211–226.
   Web of Science ®Google Scholar
• SIDDIQUI 0, CHIEN YW: Nonparenteral administration of peptide and protein drugs. Grit. Rev. Thor. Drug Carr, Syst, (1987) 3:195–208.
   Google Scholar
• WEARLEY LL: Recent progress in protein and peptide delivery by noninvasive routes. Grit. Rev. Then Drug Carr. Syst. (1991) 8(4):331–394.
   PubMed Web of Science ®Google Scholar
• •State of the art report.
   Google Scholar
• BODDE HE, VERHOEF JC, PONEC M: Transdermal pep-tide delivery. Biochem, Soc. Trans. (1989) 17:943–946.
   PubMed Web of Science ®Google Scholar
• PARASRAMPURIA D, PARASRAMPURIA J: Percutaneous delivery of proteins and peptides using iontophoretic techniques. J.Pharm, Then (1991) 16(1):7–17.
   Web of Science ®Google Scholar
• DE VRIES ME, BODDE HE, VERHOEF JC, JUNGINGER HE: Developments in buccal drug delivery. Grit, Rev, Then Drug Carr, Syst, (1991) 8 (3) :271–303.
   PubMed Web of Science ®Google Scholar
• •Good introduction to this rapidly developing field.
   Google Scholar
• WEBER CJ, JICHA D, MATZ S et al.: Passage of somatosta-tin analogue across human and mouse skin. Surgery (1987) 102(6):974–981.
   PubMed Web of Science ®Google Scholar
• VAN DER ZEE CE, BRAKKEE JH, GISPEN WH: a-MSH and ORG.2766 in peripheral nerve regeneration: different routes of delivery. Eur, J. Pharmacol. (1988) 147(3):351–357.
   Google Scholar
• DAWSON BV, HADLEY ME, KREUTZFELD K et al.: Trans-dermal delivery of a melanotropic peptide hormone analogue. Life Sci. (1988) 43(14):1111–1117.
   PubMed Web of Science ®Google Scholar
• DAWSON BV, HADLEY ME, LEVINE N et al.: In vitro trans-dermal delivery of a melanotropic peptide through hu-man skin. J. Invest. Dermatol. (1990) 94(4):432–435.
   PubMed Web of Science ®Google Scholar
• FLEISHER D, NIEMIEC SM, OH CK et al.: Topical delivery of growth hormone releasing peptide using liposomal systems: an in vitro study using hairless mouse skin. Life Sci. (1995) 57:1293–1297.
   PubMed Web of Science ®Google Scholar
• LIEDTKE RK, SORGER M, MERK F, VETTER H: Transder-mal administration of insulin in type II diabetics. Re-sults of a clinical pilot study. Arzneimittelforschung (1990) 40(8)884–886.
   Google Scholar
• WANG LF, UN JY, HSIEH KH, UN RH: Epicutaneous expo-sure of protein antigen induces a predominant T112-like response with high IgE production in mice. J. Im-munol. (1996) 156(104077–4082.
   Google Scholar
• CARMICHAEL AJ: Skin sensitivity and transdermal drug delivery. A review of the problem. Drug Saf (1994) 10(2):151–159.
   PubMed Web of Science ®Google Scholar
• •Complements [25].
   Google Scholar
• SINGH J, BHATIA KS: Topical iontophoretic drug deliv-ery: pathways, principles, factors and skin irritation. Med. Res. Rev. (1996) 16(3):285–296.
   PubMed Web of Science ®Google Scholar
• BERNER B, WILSON DR, STEFFENS RJ et al.: The relation-ship between pKa and skin irritation for a series of ba-sic penetrants in man. Fundam, AppL ToxicoL (1990) 15 (4):760–706.
   PubMedGoogle Scholar
• GROSSMANN M, JAMIESON MJ, KELLOGG DL JR et al.: The effect of iontophoresis on the cutaneous vasculature: evidence for current-induced hyperemia. Microvasc, Res. (1995) 50(3):444–452.
   Google Scholar
• LAPORTE M: Contact eczema and drug ionization. Acta. Belg, Med. Phys. (1984) 7(3):97–99.
   PubMedGoogle Scholar
• Lesions and shocks during iontophoresis. Health Dev, (1997) 26(3):123–125.
   PubMedGoogle Scholar
• BARBAUD A, MODIANO P, COCCIALE M, REICHERT S, SCHMUTZ JL: The topical application of resorcinol can provoke a systemic allergic reaction. Br. J. Dermatol. (1996) 135(6):1014–1015.
   PubMed Web of Science ®Google Scholar
• GOMPER G, KROLL DM: Driven transport of fluid vesi-cles thruogh narrow pores. Phys. Rev. E. (1995) 52 (4) :4198–4208.
   PubMed Web of Science ®Google Scholar
• MAZER NA, HEIBER WE, MOELLMER JF et al.: Enhanced transdermal delivery of testosterone: a new physiologi-cal approach for androgen replacement in hypogona-dal men. J. Control. Rel. (1992) 19:347–362.
   Google Scholar